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ABSTRACT 
Protection against atherosclerosis by a non-native pentameric CRP that shares its ligand 




C-reactive protein (CRP) is an acute phase protein of the innate immune system that has been 
evolutionarily conserved. Human CRP is known to exist in two different pentameric 
conformations; native CRP and non-native CRP that possess differential ligand recognition 
functions. The structure of CRP evolved from arthropods to humans, in terms of subunit 
composition, disulfide bonds, and glycosylation pattern. Along with change in structure, the gene 
expression pattern of CRP also evolved from a constitutive protein in lower invertebrates to an 
acute phase protein in humans. The objective of this study was to determine the function of a 
non-native pentameric CRP, that binds to atherogenic LDL, in atherosclerosis and compare the 
ligand recognition functions of human pentameric CRP with an evolutionary distant CRP for 
understanding the evolution of the structure of CRP. Additionally, in vitro reporter gene assays 
were used to gain further insight into the regulation of human CRP gene expression by an IL-6 
inducible transcription factor, STAT3. We observed that CRP, in its non-native pentameric 
conformation, binds to atherogenic LDL and slows the progression of atherosclerosis in a site-
specific manner in high fat diet fed LDLR-/- mice. Further, we observed that the ligand 
recognition function of CRP from an evolutionary conserved species, Limulus polyphemus, is 
different than that of native pentameric human CRP, but overlaps that of non-native pentameric 
human CRP. Lastly, we screened the proximal 300 bp region of the CRP promoter and identified 
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a novel STAT3 binding site at position -134 located upstream of the previously identified, 
transcriptionally active STAT3 site at -108. In conclusion, non-native pentameric human CRP is 
an atheroprotective molecule whose ligand recognition functions exhibit similarity with CRP 
from an evolutionarily distant species. IL-6 mediated transcriptional regulation of human CRP is 
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C-reactive protein (CRP) is an acute phase protein of the human innate immune response 
system that has been conserved during evolution. CRP was named so because it was discovered 
to precipitate the C-polysaccharide of the pneumococcal cell wall (1). CRP belongs to the 
phylogenetically conserved family of pentraxins and it falls in the category of short pentraxins 
along with serum amyloid P (2). The primary ligand-binding specificity of CRP is for 
phosphocholine (PCh)-containing substances, and this PCh-binding property of CRP is calcium 
dependent (3). CRP pentamer has a recognition face, that contains binding sites for PCh and 
calcium ions (Ca2+), and an effector face that lies opposite to the recognition face (4,5). 
Structure of CRP 
Human CRP is a pentamer composed of five identical non-covalently linked subunits 
(Fig 1.1). Each subunit has a molecular weight of approximately 23 kDa and is composed of 206 
amino acids. The five subunits of pentameric CRP are symmetrically arranged around a central 
pore, with every subunit folded into two antiparallel b sheets forming a flattened jelly-roll 
topology. Each subunit has a binding site for PCh, the primary ligand for CRP, and Ca2+. The 
PCh-binding site lies on the recognition face of the CRP pentamer and it is made up of two 
bound Ca2+ along with a hydrophobic pocket formed by three critical amino acids, Phe66, Thr76, 
and Glu81. The phosphate group of PCh interacts with the two Ca2+ while the choline moiety of 
PCh interacts with Phe66 (3 methyl groups of choline) and Glu81 (positively charged nitrogen 
atom of choline). Thr76 indirectly participates in forming the PCh-binding site by creating an 





Figure 1.1: Crystal structure of CRP complexed with PCh in the presence of Ca2+. The 
PCh moiety is represented in red while the Ca2+ are represented in green (Shrive AK, et 
al., 1996, Nature Struct. Biol. 3:346: used with permission). 
 
At the PCh-binding pocket, CRP also binds to phosphoethanolamine (PEt)-containing 
substances, cholesterol, and histones (9,10). The face opposite to the recognition face, is the 
effector face of the CRP pentamer. The effector face interacts with C1q, the classical 
complement pathway protein, and Fcγ receptors via a cleft that extends from the center of each 
subunit to the central pore. The amino acids critical for forming the C1q binding site on CRP are 
Asp112 and Tyr175 (4,11-12). A slight conformational change is required in the CRP pentamer for 
optimal binding of C1q to ligand-complexed CRP and the ligand to which CRP is complexed 








Functions of CRP 
CRP is a key component of the inflammatory response in humans and its association with 
various disease pathologies such as atherosclerosis, pneumococcal infection, rheumatoid 
arthritis, systemic lupus erythematosus (SLE), and cancer has been studied. It has been shown to 
bind to substances containing exposed PCh-groups such as bacterial pneumococcal C-
polysaccharide, low-density lipoprotein (LDL), and apoptotic or damaged cells (14-16). Ligand-
complexed CRP activates the classical complement pathway via binding to C1q. This ligand-
bound CRP-C1q complex mediates the clearance of pathogens and cellular debris (4,11). In 
addition to activation of complement, it also induces phagocytosis via indirect interaction with 
Fcγ receptors on macrophages (12). 
CRP has been shown to exist in two pentameric structural conformations: native and non-
native. Native pentameric CRP, at physiological pH, recognizes and binds to molecules with 
exposed PCh-groups while non-native pentameric CRP recognizes and binds to immobilized 
proteins exhibiting malformed or misfolded proteins in addition to binding to molecules with 
exposed PCh-groups and this interaction occurs in conditions resembling inflammatory states 
(17).  
CRP has been shown to be protective against bacterial infection (Streptococcus 
pneumoniae) where, in its native pentameric conformation it binds to the exposed PCh-groups on 
the bacteria and then this ligand-complexed CRP binds to C1q and activates the classical 
complement pathway mediating pathogen clearance. In this way, native CRP is protective 
against early stages of pneumococcal infection (18-20). Non-native pentameric CRP, on the 
other hand, binds to immobilized Factor-H along with binding to exposed PCh-groups on the 
bacteria. Due to this dual functionality of non-native pentameric CRP, it is protective against 
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both early and late stages of pneumococcal infection (21-22). In addition to protection against 
Streptococcus pneumoniae, CRP has been shown to increase survival of mice injected with 
Salmonella typhimurium (23). 
The association of CRP with chronic inflammatory conditions such as atherosclerosis, 
has been described in light of its increased serum levels (24). CRP has been shown to bind to 
modified or atherogenic forms of LDL along with its co-localization with macrophages and 
modified LDL at atherosclerotic lesions (25). In a study using a mouse model with human like 
hypercholesterolemia, CRP has been shown to slow down the progression of atherosclerosis 
(26). In a mouse model of SLE, human CRP was shown to prevent and reverse nephritis (27). 
Also, CRP has been shown to protect myeloma cells from chemotherapy-induced apoptosis (28). 
 
Significance of Serum CRP levels 
CRP is an acute phase plasma protein in humans, concentration of which increases in 
acute, chronic and some non-inflammatory conditions (29, 30). The serum concentration of CRP, 
in a healthy individual, is 0.8-3 mg/L but, following the onset of an inflammatory state the 
concentration of CRP increases rapidly (Fig. 1.2). This increase in serum concentration ranges 
from 1-3 mg/L to several hundred and thousand-fold higher (31). Following the resolution of 
inflammation, there is an equally rapid decrease in CRP concentration down to basal levels (32). 
Therefore, for diagnosis of various acute and chronic inflammatory diseases, serum CRP levels 
are used as a marker of inflammation.  
Elevation of CRP concentration above baseline levels was recommended by the 
American Heart Association to be used as a predictor for cardiovascular diseases such as 
atherosclerosis (24). Due to variations in the serum CRP levels in healthy population, it is not 
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clear whether we can use elevated CRP levels as an independent risk factor for prediction, 
diagnosis, and pathogenesis of any inflammatory disease (33,34). 
 
 
Figure 1.2. Percent change in plasma concentrations of various acute phase proteins 
following an inflammatory stimulus (Gabay C, et al., 1999, N. Engl. J. Med. 340, 448-54: 
used with permission). 
 
CRP and Atherosclerosis 
Atherosclerosis is a chronic inflammatory disease that is initiated by the retention of 
lipids along the arterial lining with subsequent modification of LDL. Modified LDLs, often 
characterized as atherogenic LDL, are engulfed by macrophages, which then transform into 
lipid-loaded foam cells. Foam cells are pro-inflammatory and initiate the process of lesion 
formation (35). The generation of extracellular acidic environment, lipid retention, lipoprotein 
modification, and conversion of macrophages into LDL-loaded foam cells are the hallmarks of 
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such localized inflammatory atherosclerotic lesions. The development of an acidic extracellular 
milieu may be due to macrophage activation, hypoxia, lactate generation and proton generation 
(36-41).  
CRP has been implicated in the pathogenesis of atherosclerosis, yet its function remains 
undefined. Human CRP, apart from being present in the circulation, is also deposited in the 
extracellular matrix of localized inflammatory sites such as atherosclerotic plaques in both 
humans and animal models (42-45). Previous studies have examined the binding of native 
pentameric CRP to two atherogenic forms of LDL: enzymatically modified LDL (E-LDL) and 
oxidized LDL (ox-LDL). CRP binds to E-LDL at physiological pH in a Ca2+-dependent and 
PCh-inhibitable manner. This binding is dramatically increased in the presence of acidic pH 
(39,41). CRP does not bind to ox-LDL at physiological pH but gains the ability to bind to ox-
LDL at acidic pH. Acidic pH does not monomerize CRP, and the change in the binding is 
reversible on pH neutralization. This binding of CRP to ox-LDL is not Ca2+-dependent, 
indicating that acidic pH causes a conformational alteration of the CRP pentamer, and exposes a 
functional site in CRP that is buried at physiological pH. Along with structural studies of CRP at 
acidic pH, these results suggested that inter-subunit interactions were involved in the acidic pH 
induced ‘loosening’ of the CRP pentamer (46). 
In studies using animal models of atherosclerosis, native human CRP has not been shown 
to have an effect on the initiation and progression of atherosclerosis (47-50). However, in vitro 
studies have shown that CRP, in its alternate structural conformation, has the ability to bind to 
modified atherogenic LDL, such as ox-LDL. CRP has also been shown to prevent macrophage 
foam cell formation in vitro. Because the presence of an acidic environment is a hallmark of 
atherosclerotic lesions, the absence of such inflammatory environment in these rodent models of 
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atherosclerosis might explain the ineffectiveness of human CRP as the CRP administered to 
these animals might not have undergone the low pH-induced structural modification that is 
required for it to bind ox-LDL and prevent ox- LDL induced foam cell formation (51). In this 
dissertation, in specific aim 1, the anti-atherosclerotic function of CRP in its non-native 
pentameric structural conformation will be investigated.  
Rationale and Hypothesis 
Acidic pH transforms native pentameric CRP pentamer into a ‘loosened’ pentamer 
confirmation and exposes the hidden ox-LDL binding site that was previously buried. As the pH 
of the atherosclerotic lesion in animal models may not be acidic, to test the role of CRP in 
atherogenesis it is essential to have a modified CRP that can bind to ox-LDL at physiological 
pH. We hypothesize that site-directed mutagenesis of the amino acids involved in the inter-
subunit interactions will result in a ‘loosened’ pentamer that can bind to ox-LDL at physiological 
pH. Such mutant CRP, created by site-directed mutagenesis, that displays the ability to bind to 
ox-LDL at physiological pH can either prevent or delay the initiation and progression of 
atherosclerosis. 
Evolutionary Conservation of CRP 
CRP is an evolutionarily conserved protein as, across the animal phyla, it has been found 
in every organism where its presence has been sought (52) (Fig 1.3).The American horseshoe 
crab Limulus Polyphemus, an arthropod, has been considered to be a living fossil as it diverged 
approximately 300-500 million years ago and is the best characterized invertebrate source of 
pentraxin proteins. In the hemolymph of Limulus Polyphemus, hemocyanin is the predominant 
protein followed by pentraxins as the second most abundant protein. Amongst the pentraxins 
CRP, SAP-like pentraxin, and limulin are present in the hemolymph of these animals (53). Three 
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subunits of Limulus CRP have been established based on the amino acid sequence, disulfide 

















Figure 1.3. Phylogenetic tree of CRP (Lee PT, et al., 2017, Fish Shellfish Immunol. 65, 
42-51: used with permission). 
 
During evolution, the structure of CRP changed. Unlike human CRP, which is a 
pentamer, Limulus CRP is a stack of two hexamers composed of six identical subunits (~12 
subunits) (54) although the region in human CRP that is critical for PCh-binding and Ca2+ ion 
binding show sequence identity with Limulus CRP (55). Human CRP, in its native pentameric 
conformation, binds to molecules and cells that have exposed PCh residues in a Ca2+-dependent 
manner. Human CRP, in its alternate or non-native pentameric conformation recognizes an, as 
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yet, undefined pattern on immobilized, aggregated and conformationally altered proteins. The 
alternate structural conformation of CRP is achieved in response to inflammatory conditions 
characterized by acidic pH and oxidative stress (17). As opposed to human CRP, Limulus CRP is 
a glycoprotein. Published literature suggests that there are three distinct pentraxin species in 
Limulus depending upon its PCh, PEt, and sialic acid binding properties: CRP, SAP-like protein, 
and limulin respectively (54-59). Not much is known about the functions and the structure-
function relationships of Limulus CRP. Specific aim 2 of this dissertation is designed to explore 
the functions of Limulus CRP. 
Rationale and Hypothesis 
These invertebrates lack an adaptive immune system, therefore humoral components such 
as the pentraxins are implicated in non-specific host defense and innate immunity that has been 
evolutionarily conserved. The discovery of Limulus CRP and its study provides important 
insights in the evolution of pentraxins and subsequent divergence of function in comparison to 
human CRP, over the period of time. The differences in the overall structure and glycosylation 
states between invertebrate and vertebrate CRP indicate that the functions of CRP are also 
specific. The evolutionary conservation of CRP from invertebrates to humans and its high 
circulating concentration in an ancient invertebrate provides insight into the importance of CRP 
and its biological functions. We hypothesize that, unlike human CRP, Limulus CRP does not 
require a structural change to recognize and bind to pathogenic and toxic proteins formed due to 
harsh environments where these arthropods live. 
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Regulation of CRP gene expression 
Like its structure, the level of CRP gene expression also changed during evolution. In 
lower invertebrates such as the American horseshoe crab Limulus polyphemus, CRP is a 
constitutively expressed protein and is present in the hemolymph at all times at high 
concentration. In mice, CRP gene is expressed at a very low level. In rats, CRP is a minor acute 
phase protein. In humans, CRP is the prototypic acute phase protein whose serum level increases 
several folds in response to inflammatory conditions. CRP serves as a non-specific biomarker of 
inflammation and its serum concentration is often measured to monitor the resolution of 
inflammation. Currently, experiments are underway in several laboratories to understand the 
mechanism of human CRP gene expression in hepatocytes (32, 40, 60-62).  
Human CRP is a hepatic protein that is encoded by a single gene located on the short arm 
of chromosome 1(62). Several hepatic cell lines such Hep3B, HepG2, and Huh7 are used to 
study CRP gene expression as the availability of primary human hepatocytes is limited. Various 
cytokines such as interleukin 6 (IL-6), interleukin 1β (IL-1β), TNFα, TGFβ, and IL-17 regulate 
CRP gene expression via activation of specific transcription factors (63-67). Hep3B is the most 
commonly use cell line model to study CRP gene expression and the cytokines that majorly 
regulate gene expression in these cell lines are IL-6 and IL-1β (68). IL-6 increases CRP 
transcription through activation of transcription factors CCAAT/enhancer-binding protein β 
(C/EBPβ) and signal transducer and activator of transcription 3 (STAT3) (69-72). IL-1β is 
insufficient by itself to activate CRP gene expression, however, when acting synergistically with 
IL-6, it enhances the effects of IL-6 by activating the transcription factor nuclear factor-kappa B 
(NF-κB) (73-75). Apart from these cytokine-activated transcription factors, CRP gene expression 
is regulated by constitutively expressed transcription factors such as HNF-1, HNF-3, C/EBPδ, 
 27 
RBP-Jκ, and Oct-1 (76-81). 
It has been shown that the proximal 157 bp region of the CRP promoter at the 5’ flanking 
region is sufficient for the synergy between IL-6 and IL-1β and this region of the CRP promoter 
contains binding sites for multiple transcription factors including cytokine-activated transcription 
factors and constitutively expressed transcription factors. Previous studies have identified the 
binding sites at which these transcription factors bind and induce and regulate CRP gene 




Figure 1.4. The -300 to +3 region of the proximal promoter region of the CRP gene is 
shown. The binding sites of various transcription factors on the promoter are boxed 
(adapted from Prem Prakash Singh et al., 2007, J Immunol. 178, 7302-09). 
         
STAT3 is a major transcription factor activated by IL-6. STAT3 binds to specific 
response elements in the promoter regions containing TT(N)4AA or TT(N)5AA motifs. A 
functional, STAT3-binding site, centered at position -108 on the CRP promoter has been 
previously identified when searched within the first 157 bp region of the promoter (83). 
However, the data suggest that this STAT3 site is not the only site through which IL-6 activated 
STAT3 works.  STAT3 induces its effect by binding to both TT(N)4AA and TT(N)5AA 
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sequences in the promoter. In specific aim 3 of this dissertation, we will identify putative 
STAT3-binding sites in the 300 bp region of proximal CRP promoter and elucidate the role of 
STAT3 in CRP gene expression. 
Rationale and hypothesis 
Previously, it has been reported that, in response to IL-6, the induction of CRP gene 
expression driven by the first 300 bp region is higher than when driven by only 157 bp of the 
promoter. We hypothesize that there are more STAT3-binding sites (besides the one present at 
position -108) on the CRP promoter, likely to be located within the -157 to -300 bp region that 
might participate in inducing and regulating CRP gene expression. 
For better understanding the role of CRP in light of its structure-function relationship, we 
had three major questions. The first question entailed to the function of a structurally altered 
pentameric CRP (non-native CRP) in the initiation and progression of atherosclerosis, whose 
ligand recognition function differs from native CRP. For the second question, we wanted to learn 
if this structure-dependent ligand recognition function of human CRP diverged during evolution 
by using CRP from an evolutionarily distant species, Limulus polyphemus. And lastly, for the 
third question, we wanted to better understand the transcriptional regulation of CRP gene 
expression by studying the function of an IL-6 inducible transcription factor, STAT3. These 








1.  Determine the atheroprotective ability of human CRP in a murine model of 
atherosclerosis. 
a. Identification of a CRP mutant created by site-directed mutagenesis which binds to 
immobilized ox-LDL at physiological pH. 
b. Determine the effects of the CRP mutant capable of binding to ox-LDL on the 
development of atherosclerosis employing LDL receptor knockout mouse model of 
atherosclerosis. 
• The findings are presented in Chapter 2  
2. Purification and characterization of CRP from the hemolymph of Limulus Polyphemus. 
a. Purification of PCh-binding and  PEt-binding protein. 
b. Deglycosylation of PCh-binding and PEt-binding proteins. 
c. Define ligand-binding properties of native and deglycosylated PCh-binding and PEt-
binding proteins. 
• The findings are presented in Chapter 3  
3. Investigating the role of transcription factor STAT3 in human CRP expression in hepatic 
cells. 
a. Screening for STAT3-binding sites in the first 300 bp region on the CRP promoter. 
b. Confirm the binding of STAT3 to the putative STAT3-binding sites identified.  
c. Determine if any of the putative STAT3-binding sites are transcriptionally active. 
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Abstract 
Objective- C-reactive protein (CRP) is a pentameric, acute phase protein that exists in three 
structural conformations: native pentameric, non-native pentameric, and monomeric. In vitro, 
native CRP does not bind to oxidized LDL, however, non-native CRP binds to oxidized LDL as 
it has been proposed that CRP changes its structure at sites of inflammation. In vivo, native CRP 
is neither pro-atherosclerotic nor atheroprotective and we hypothesize that this ineffectiveness of 
native CRP is due to an inappropriate inflammatory microenvironment in the arterial wall that 
stalls CRP from changing its structure. 
Methods and Results- In the current study, we evaluated the impact of a mutant CRP 
F66A/T76Y/E81A CRP, that is capable of binding to oxidized LDL at physiological pH, on the 
development of atherosclerosis. LDLR-/- mice were fed on a high fat diet for 10 weeks and 
administered with and without  F66A/T76Y/E81A CRP. We found that administration of 
F66A/T76Y/E81A CRP significantly reduced the extent of atherosclerotic lesion in the whole 
aorta and slowed the progression of atherosclerosis, but it did not show an effect on the 
development and progression of atherosclerosis in the aortic root. F66A/T76Y/E81A CRP was 
found to be localized in the atherosclerotic lesion in the aorta. Also, F66A/T76Y/E81A mutant 
CRP administration did not alter the plasmid lipid levels. 
Conclusion- F66A/T76Y/E81A CRP showed a site-specific atheroprotective effect via 
dwindling atherosclerotic lesion development and progression in the aorta. Overall, the data 
indicates that CRP is an atheroprotective molecule and such mutant CRP might represent as a 





ApoE-/-                               Apolipoprotein E knockout 
ApoB100/100 LDLR-/-             Apolipoprotein / low density lipoprotein receptor knockout 
Ca2+                                 Calcium-ions 
CRP                                C-reactive protein 
DI                                    Distilled water 
E-LDL                            Enzymatically modified low density lipoprotein 
HDL                               High density lipoprotein 
HFD                                High fat diet 
LDL                                Low density lipoprotein 
LDLR-/-                           Low density lipoprotein receptor knockout 
mCRP                             Monomeric C-reactive protein 
mut CRP                         F66A/T76Y/E81A mutant CRP 
Ox-LDL                         Oxidized low density lipoprotein 
ORO                               Oil Red O 
PCh                                 Phosphocholine 
TBS-Ca                            TBS, pH 7.2, containing 0.1% gelatin, 0.02% Tween 20 and 2 mM CaCl2 





Atherosclerosis, an inflammatory disease of the heart, is caused by the dysfunction of the 
endothelial wall leading to infiltration, deposition and subsequent modification of low-density 
lipoprotein (LDL) along arterial lining (1-3). LDL, modified either by oxidation [oxidized LDL 
(ox-LDL)], acetylation [acetylated LDL] or enzymatic modification [enzymatically modified 
LDL (E-LDL)], is recognized and engulfed by macrophages to form foam cells. Modification of 
LDL and formation of foam cells via macrophages are the two primary events marking the 
hallmark of the development of atherosclerosis (3-5). Modified LDL has also been shown to 
induce the expression of chemokines, pro-inflammatory cytokines, and other mediators of 
inflammation at sites of atherosclerotic lesions. The pH in atherosclerotic lesions has also been 
shown to be acidic due to proton and/or lactate generation, hypoxia, and activated macrophages 
(6-10).  
C-reactive protein (CRP) is an acute phase protein of hepatic origin. Structurally, it is a 
pentamer of identical subunits, in which each subunit contains a phosphocholine (PCh)-binding 
site and calcium ion (Ca2+)- binding site. It binds to PCh and PCh-containing ligands in a Ca2+- 
dependent manner and Glu81, Phe66 and Thr76 are critical for this interaction. In a normal 
physiological environment, CRP exists as native pentameric CRP, but upon exposure to a 
localized pathological and inflammatory environment, it changes its structure to a non-native 
pentameric state (11-17). This structural change of CRP from its native to non-native pentameric 
state upon sensing of an inflammatory environment is reversible. Native CRP has been shown to 
bind to E-LDL but not to ox-LDL. Its binding to ox-LDL is dependent on the presence of an 
inflammatory microenvironment since CRP is able to change its native pentameric structure to a 
non-native pentameric structure at acidic pH (18-23). In addition to this binding capability, it has 
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also been found to co-localize with LDL and macrophages in atherosclerotic lesions in both 
human and experimental animals, further suggesting a function in atherosclerosis (24-28). 
Previously, native CRP has been investigated for its role in the development of 
atherosclerosis using several different murine models of atherosclerosis such as ApoE -/- 
(Apolipoprotein E knockout), LDLR -/- (LDL receptor knockout), and ApoB 100/100 LDLR -/- 
(Apolipoprotein B100/100/. LDL receptor knockout). The conclusion of the studies was that CRP 
was neither pro-atherogenic nor anti-atherosclerotic (29-32). One possible explanation for the 
observed lack of effect of native CRP on atherosclerosis in these studies is that the mouse models 
do not possess a suitable acidic microenvironment to induce native CRP to undergo structural 
change to its non-native structural conformation.  
In the present study, we examined the effect of F66A/T76Y/E81A mutant CRP (mut 
CRP) on the development of atherosclerosis in LDLR-/- mice fed on a high fat diet (HFD). We 
hypothesize that administration of this mut CRP, that binds to ox-LDL under physiological 
conditions, would display beneficial effects on atherosclerosis in mice. In this study, we tested 
this hypothesis by comparing the extent of atherosclerosis in HFD fed LDLR-/- mice, injected 
with and without mut CRP. We found that administration of mut CRP significantly reduced the 
en face atherosclerotic lesion area and slowed the progression of the disease in the whole aorta, 
but, had no effect on the development of atherosclerosis in the aortic root. Overall, the data 
indicate that administration of mut CRP does exibhit an atheroprotective effect in mice and it 







Construction, Expression and Purification of mut CRP (F66A/T76Y/E81A Mutant CRP)  
The construction of mut CRP has been described earlier (33). Briefly, a clone of 
F66A/T76Y/E81A stably transfected in CHO cells was used for cell culture. Cells were cultured 
in SFM media supplemented with 1% FBS and 1% Penicillin-Streptomycin stock and grown. 
Media, containing mut CRP, was collected and centrifuged at 10,000 rpm for 10 minutes and 
mut CRP was purified from cell culture supernatants by a Ca2+-dependent affinity 
chromatography on a Phosphoethanolamine-conjugated Sepharose column followed by gel 
filtration chromatography on a Superose 12 column, as described previously (33). 
Ox-LDL Binding Assay 
Binding activity of mut CRP for ox-LDL at physiological pH was evaluated by an 
ELISA- based binding assay. Briefly, microtiter wells were coated with ox-LDL (10 µg/ml 
diluted in 1X TBS) and incubated overnight at 4 °C. Wells were blocked with 0.5% gelatin for 
45 minutes followed by addition of purified CRP [Wild type (WT) and mut CRP], diluted in 
buffer containing 1X TBS, 0.1% gelatin, 0.02% Tween 20, and 2 mM CaCl2 (TBS-Ca, pH 7.2). 
Wells were incubated with CRP for 2 h at 37 °C. Following CRP incubation, wells were washed 
with TBS-Ca and rabbit anti-CRP antibody (Sigma, cat#  C3527-1VL; diluted 1/1000 in TBS-
Ca), was added (100 μl /well, 1 h at 37 °C) to detect bound CRP. HRP-conjugated donkey anti-
rabbit IgG (GE Healthcare, cat# GENA934), diluted in TBS-Ca, was used (100 μl /well, 1 h at 37 
°C) as the secondary antibody. Color was developed using ABTS as the substrate, and the 




Eight-week-old male LDLR-/- mice in the C57BL/6 background (#002207, Jackson 
Laboratory, Bar Harbor, ME, USA) were placed on a HFD consisting of 21% fat and 0.2% 
cholesterol (TD.88137; Envigo) for 10 weeks. After 1 week of HFD, mice were given injections 
of mut CRP (50 µg/injection) every other day via alternating intra-venous (IV) and intra-
peritoneal (IP) routes for upto 9 weeks as depicted in (Fig 2.1). Control mice were injected with 
an equivalent volume of vehicle (TBS). The dosage of mut CRP to be injected into mice was 
decided on the basis of its rate of clearance, as previously performed pharmacokinetic studies 
demonstrated the rate of clearance of mut CRP in vivo to be approximately 15-20 hours (33). At 
two weeks intervals, groups (n=6) of mice were fasted overnight, anesthetized and anti-
coagulated blood samples were obtained by cardiac puncture prior to cardiac perfusion with ice-
cold neutral buffered 10% formalin induced (Sigma, cat # HT-501128). Hearts and aortas were 
cleared of adventitial fat and excised. Aortas were saved in 10% formalin at 40 C and heart tissue 
was embedded in OCT medium and stored at -80 °C as done previously (34). All mice were 
housed in a pathogen-free, temperature- and humidity-controlled room in the Animal Research 
Facility at East Tennessee State University. All mice studies were approved by and conducted in 
accordance with the guidelines administered by the Institutional Animal Care and Usage 
Committee of East Tennessee State University and in conformity with the Public Health Service 






Figure 2.1: A schematic representation of the protocol used during the study. 
 
Analysis of Atherosclerosis 
Atherosclerotic lesions throughout the thoracoabdominal aorta were evaluated in 
formalin-fixed aortae opened longitudinally (en face) and stained with 0.5% Sudan IV, as 
described previously (34). The extent of the total aortic lumen stained positive with Sudan IV 
was quantified in digital images using Image J (35). For evaluation of atherosclerosis in the 
aortic root , cross-section ( 8-µm) of frozen OCT-embedded heart tissue were collected on 
microscope slides starting at the first appearance of the aortic valve leaflets until the 
disappearance (~ 48-72 sections per mouse). Every other cross-section spanning the entire aortic 
root were stained with Oil-red O (ORO) for lipids and counterstained with hematoxylin. Digital 
photomicrographs were acquired with an Olympus BX41 microscope equipped with a CCD 
color camera (QImaging) and the area staining positive for ORO was quantified using the Image 
J software as previously described (34). All measurements were performed independently in a 
blind fashion. 
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Formalin-fixed, Sudan IV stained aortae were first washed with water for 30 minutes 
followed by alcohol dehydration through a series of graded alcohol washes. Aortae were washed 
first with 70% alcohol for 30 minutes followed by 80% alcohol for 30 minutes, and then 95% 
alcohol for 30 minutes. Post-dehydration, aortae were washed twice with xylene with each 
xylene wash lasting for 30 minutes (36). Aortae were then washed with 1X PBS for 5 minutes 
and immunostaining for mut CRP was performed using Vectastain ABC Elite kit (Vector 
laboratories, cat # PK-6100) and manufacturer’s instructions were followed. Bound CRP was 
detected with rabbit anti-CRP (Sigma, 10 µg/ml /aorta). Biotinylated goat-anti rabbit IgG was 
used as the secondary antibody. Color was developed using two different peroxidase substrates: 
Brown colored reaction produced by DAB (Vector laboratories, ImmPACT DAB, cat # SK-
4105) and blue colored reaction produced by TMB (Vector laboratories, cat # SK-4400). 
Manufacturer’s instructions were followed.  
Measurement of Lipids in the Plasma of LDLR-/- mice 
Plasma was collected from whole blood via cardiac puncture at the time of sacrifice using 
EDTA as an anti-coagulant. Plasma lipid levels [HDL (high density lipoprotein) and 
LDL/VLDL] were analyzed using Cholesterol Assay Kit- HDL and LDL/VLDL (abcam; cat # 
ab65390). Lipid levels were measured in the pooled plasma samples at every given week point 







For atherosclerosis samples, data were analyzed using non-parametric test (Mann-
Whitney test) using Graphpad Prism software. p < 0.05 was considered statistically significant. 
For plasma lipid analysis, data is represented as mean + standard deviation and unpaired student 





























F66A/T76Y/E81A Mutant CRP Binds to ox-LDL at Physiological pH 
As shown previously (33), the overall structure of mut CRP was pentameric and the 
mutation did not affect the stability of the protein in vivo. Additionally, mut CRP was found to 
circulate freely in the mouse serum. The binding activity of mut CRP and WT CRP for ox-LDL 
at physiological pH was assessed and mutant CRP bound to ox-LDL in a dose dependent manner 





Figure 2.2: F66A/T76Y/E81A mutant CRP binds to ox-LDL at physiological pH unlike 
WT CRP. Microtiter wells were coated with ox-LDL. WT CRP (red) and mut CRP 
(black) diluted in TBS-Ca were then added to the wells in increasing concentration. 
Bound CRP was detected by using rabbit anti-CRP antibody and HRP-conjugated donkey 















This result show that mut CRP has the ability to recognize and bind to ox-LDL in vitro, 
in the absence of an acidic environment. Furthermore, this binding is PCh-independent since the 
PCh binding site of mut CRP is abolished (33).  
Chronic Treatment with F66A/T76Y/E81A Mutant CRP Significantly Reduces 
Atherosclerotic Lesion Formation in the Aortae of LDLR-/- mice 
To assess the potential therapeutic effects of mut CRP on atherosclerotic burden in the 
early stages of atherosclerosis, LDLR-/- mice were fed on HFD for 1 week and randomly 
assigned to receive injections of vehicle or mut CRP (50 µg/injection). The experiment was 
performed twice with n = 6 mice in each group at every given data collection time point. In the 
first set of experiment, administration of mut CRP had no effect on the degree of atherosclerotic 
lesion throughout the aorta at 1, 3, and 5 weeks. However, after 7 and 9 weeks of mut CRP 
treatment,  the total atherosclerotic lesion area was significantly lower when compared to the 
lesion area in untreated mice (Fig 2.3 B). In comparison to untreated mice, the median aortic 
lesion area was reduced by 29% after 7 weeks  (p = 0.05) and 33% after 9 weeks (p = 0.002) in 
mice injected with mut CRP. After 5 weeks, the atherosclerotic lesion area was 15% less in mut 
CRP treated mice when compared to untreated mice, however the reduction did not reach 
statistical significance (p = 0.06). In untreated group, the burden of atherosclerotic degree 
progressed in an incremental manner from week 1 through week 7, where it reached a plateau 
and remained constant at week 9. In contrast,  progression of atherosclerosis in mice treated with 
mut CRP also progressed incremently until week 5, but it reached a plateau and remained  
constant at week 9. 
In a replicate experiment, treatment with mut CRP did not affect the burden of 
atherosclerotic lesion area at early time points (1, 3, and 5 weeks) but, resulted in a statistically 
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significant reduction in aortic lesion area when compared to untreated mice (Fig 2.3 C). In 
comparison to the untreated mice, the lesion area in mice treated with mut CRP was reduced by 
52% after 7 weeks (p = 0.04) and 55% after 9 weeks (p = 0.03). Similar to the first experiment, 
atherosclerosis steadily increased in the untreated mice from week 1 through week 9 but similar 
disease progression was not observed in mice treated with mut CRP where the disease 
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Figure 2.3: F66A/T76Y/E81A mutant CRP reduces atherosclerosis in the aorta of 
LDLR−/−mice. Quantification of total atherosclerotic lesion area in en face aorta 
specimens from untreated and mut CRP treated LDLR−/− mice maintained on a high fat 
diet. A, A representative Sudan IV-stained aorta from male LDLR−/− mice maintained on 
a high fat diet demonstrating the spectrum of atherosclerosis is shown. The bright red 
colored areas reflect the atherosclerotic plaque or lesion (lipid rich deposits) in the aorta. 
Scale bar, 5 mm. B, Total atherosclerotic lesion coverage in en face aorta specimens from 
untreated and mut CRP treated LDLR−/− mice while C,  Quantification of total 
atherosclerotic lesion coverage in en face aorta specimens from duplicate groups of 
untreated and mut CRP treated LDLR−/− mice. Data was collected at 5 different time 
points, i.e, 1, 3, 5, 7, and 9 weeks of mut CRP administration at alternate days (TBS was 
injected for untreated group). A scatterplot of total atherosclerotic lesion coverage is 
shown. Each symbol represents the total area of the entire aorta lumen that stained 
positive with Sudan IV. Values for untreated mice are indicated in blue and those for mut 
CRP treated are indicated in green. Horizontal lines indicate the median total lesion area 
for each group. Asterisks (red) denote statistically significant differences between groups 
(*p < 0.05).  
 
 
These data, from two independently performed experiments, suggest that chronic 
treatment with mut CRP reduces the extent of atherosclerosis in the aortae of HFD fed LDLR-/- 
mice and slowed down the progression of the disease after 5 weeks of mut CRP administration. 
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Atherosclerosis in the Aortic Root of LDLR-/- mice is Unaffected by Chronic Treatment 
with F66A/T76Y/E81A Mutant CRP 
We also investigated the effects of chronic administration of mut CRP on the 
development of atherosclerosis at the level of the aortic root in two independent experiments. 
The experiments were performed with n = 6 mice in each group at every given week time point. 
In the first experiment, the median lesion area in the aortic root of mice receiving mut CRP 
injections (every alternate day) was comparatively less than that of the corresponding control 
mice, at all timepoints as determined by evaluation of ORO-stained cross-sections. However, the 
decreases in the aortic root lesion areas of mice treated with mut CRP did not reach statistical 
significance for any time point. Interestingly, although mut CRP did not significantly decrease 
the size of aortic root atherosclerotic lesion area, it did delay the progression of the disease by 
approximately two weeks as the lesion area at 5 week and 9 weeks of mut CRP administration 
was similar to the lesion area at 3 and 7 weeks of untreated mice respectively (Fig 2.4 B). In the 
second experiment, administration of mut CRP did not have any affect on the atherosclerotic 
lesion area in the aortic root at any given time point (Fig 2.4 C). The data, from the first 
experiment, suggest that mutant CRP delayed the progression of atherosclerosis in the aortic root 
of LDLR-/- mice and the data from the second experiment suggest that mutant CRP had no effect 
on atherosclerosis in the aortic root of LDLR-/- mice. Hence, the combined data suggest that 
chronic administration of mut CRP had no effect on the development of atherosclerosis in the 







Figure 2.4: F66A/T76Y/E81A mutant CRP did not affect the development of 
atherosclerosis in the aortic root of LDLR−/−mice. A, A representative ORO-stained aortic 
root section from male LDLR−/− mice maintained on a high fat diet demonstrating the 
spectrum of atherosclerosis is shown. The red colored areas reflect the atherosclerotic 
lesion (lipid rich deposits) in the aortic root. Scale bar, 100 μm. Quantification of total 
lesion area in the aortic root sections from untreated and mut CRP treated LDLR−/− mice 
maintained on a high fat diet from two independent experiments is shown (B and C 
respectively). Data was collected at 5 different time points (1, 3, 5, 7, and 9 weeks of mut 
CRP administration). A scatterplot of total atherosclerotic lesion coverage in the aortic 
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root is shown. Each symbol represents the aortic root lesion area determined for untreated 
(blue) and mut CRP treated (green) LDLR−/− mouse. Horizontal black lines indicate the 
median of total aortic root lesion area for each group of animals.  
 
F66A/T76Y/E81A mutant CRP is Detected in Atherosclerotic Lesions of LDLR-/- mice 
As shown above (Fig 2.4), chronic administration of mut CRP decreased the progression 
of atherosclerosis in the aortae of LDLR-/- mice. To elucidate, if the observed effect of reduced 
atherosclerosis in the lesions was due to chronic treatment with mut CRP, we performed, CRP 
immunostaining of aortae in both untreated and mut CRP treated mice (Fig 2.5). anti-CRP 
antibodies showed positive staining in atherosclerotic lesions of mice treated with mut CRP (Fig 
2.5 A and 2.5 B). In comparison, no staining was observed with anti-CRP antibodies in the 
atherosclerotic lesion of aorta of untreated mice (Fig  2.5 A and 2.5 B). This result shows that 
chronic administration of mut CRP results in deposition of mut CRP within lesions, where it 




Figure 2.5: F66A/T76Y/E81A mutant CRP accumulation in atherosclerotic lesions of 
LDLR−/− mice. Representative aorta from untreated and mutant CRP treated LDLR−/− 
mice subjected to immunostaining for CRP are shown. Panel 1-4 depicts an en face aorta 
through different stages of staining procedures. (1) After Sudan IV staining to visualize 
atherosclerotic lesions. Red stained areas reflect positive atherosclerotic lesions (lipid 
rich deposits) in the aorta. (2) Aorta after destaining to remove Sudan IV. White colored 
areas reflect positive atherosclerotic lesion in the aorta. (3) Following staining for CRP. 
Brown stained areas are positive for CRP. (4) Enlarged view of aortic arch of the aorta 
showing CRP positive staining. A, CRP stained aorta using DAB as substrate that 
produces a brown colored reaction. B, CRP stained aorta using TMB as substrate that 
produces a blue colored reaction.. Scale bar, 5 mm. 
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F66A/T76Y/E81A mutant CRP did not Affect the Plasma Lipids Levels of LDLR-/- mice 
In order to induce the development of atherosclerosis, LDLR-/- mice were fed HFD for 10 
weeks. Chronic administration of mut CRP had no effect on the plasma LDL and HDL levels. At 
the dose and delivery route employed, no significant difference in plasma lipid levels (both LDL 
and HDL) were observed between untreated and mut CRP treated mice at any of the time points 
examined (Table 2.1). In addition, mut CRP administration did not affect LDLR-/- mice body 
weight as the body weights of untreated and mut CRP treated mice were in the same range (data 
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Table 2.1: Plasma HDL and LDL levels after treatment with and without 
F66A/T76Y/E81A mutant CRP. Samples were collected at 6 different time points, i.e, 1, 
3, 5, 7, and 9 weeks of mut CRP administration, as indicated. Data is shown as Mean + 
SE in pooled samples from two independent experiments (n = 6/group). 
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Mut CRP has been shown to bind to modified lipoproteins such as ox-LDL, however the 
observation that plasma lipid levels were unaffected by mut CRP administration suggests that 
mut CRP did not bind or affect lipoproteins in fluid phase circulation. These data shows that the 
reduction of atherosclerosis exhibited by mut CRP was likely not due to an effect on plasma 

























In this study we investigated the effect of a non-native pentameric CRP created by site-
directed mutagenesis, F66A/T76Y/E81A mutant CRP, that does not bind to PCh since the PCh 
binding site of this mutant CRP is abolished due to mutations of critical amino acids forming the 
PCh-binding pocket, i.e., Glu81, Phe66 and Thr76, on the development of atherosclerosis 
employing LDL receptor knockout mouse model of atherosclerosis. Our major findings were as 
follows: 1) Mut CRP, unlike WT CRP, binds to ox-LDL (one of the modified forms of LDL) at 
physiological pH and it does not need the presence of an acidic environment to do so. Also, this 
binding is PCh-independent since its PCh binding site is abolished. 2) Chronic administration of 
mut CRP had an effect on the development and progression and of atherosclerosis throughout the 
aorta as evidenced by significantly reduced atherosclerotic lesion in en face aorta of LDLR-/- 
mice and halted progression of the disease post 5 weeks of mut CRP administration. 3) 
Administration of mut CRP did not affect the atherosclerotic lesion area in the aortic root of 
LDLR-/- mice. 4) Mut CRP administration did not affect the plasma lipid (HDL and LDL) levels 
of LDLR-/- mice.  
Native pentameric CRP does not recognize and bind to immobilized, aggregated, and 
pathogenic proteins but it binds to cells and molecules with PCh groups exposed on its surface, 
in a Ca2+-dependent manner (37-39). However, upon sensing a micro-inflammatory 
environment, CRP tends to gain the ability to change its pentameric structure from a native 
conformation to a non-native conformation (40). This structural conformation change, in vitro, 
can be attained by exposure to biological modifiers such as hydrogen peroxide, hypochlorous 
acid or even acidic pH but this structural change is reversible, i.e., as soon it senses physiological 
pH, it reverts back to its native pentameric conformation (18-19, 41-42). Non-native pentameric 
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CRP acquires the property to recognize and bind to immobilized, aggregated, and pathogenic 
proteins as its recognition function changes in comparison to native pentameric CRP (17, 40). 
For example, one of the functions of CRP in its non-native pentameric conformation is to bind to 
modified LDL irrespective of the presence of PCh and Ca2+. Native CRP binds E-LDL, but not 
ox-LDL. It binds to ox-LDL only if the LDL is sufficiently oxidized to expose its PCh moiety 
and hence, it recognizes and binds to the exposed PCh moiety on ox-LDL. On contrary, non-
native CRP binds to E-LDL with higher avidity compared to native CRP and it binds to ox-LDL 
irrespective of the oxidation extent of ox-LDL (18-19, 23,41,43-45).  
The effects of supplementing native CRP has been investigated using three different 
murine models of atherosclerosis (ApoE-/-, LDLR-/-  and ApoB100/100 LDLR-/-) as well as a  rabbit 
model of atherosclerosis. Supplementation of native CRP produced no effect on the development 
of atherosclerosis indicating it was neither pro-atherogenic nor anti-atherogenic (30-32, 45-53). 
However, native CRP was shown to slow the development of atherosclerosis in one study 
employing ApoB100/100 LDLR-/- mouse model, wherein these mouse models are rich in LDL and 
have been shown to develop human-like hypercholesterolemia, suggesting that CRP might have 
an atheroprotective role (29). Although investigations to determine the effects of native CRP on 
the development of atherosclerosis in animal models provided conflicting results, a study for 
investigating the effect of monomeric CRP (mCRP) on atherosclerosis using ApoE-/- mice 
showed that mCRP was atheroprotective (52). Collectively, the data suggest that native 
pentameric CRP was either incapable or only partly capable for protecting against atherosclerosis 
in animal models. One of the potential reasons for the ineffectiveness of native CRP to affect 
atherosclerosis development and progression in these murine models is that the mouse models 
does not have the required inflammatory microenvironment, needed by CRP to change its 
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structure and therefore bind to modified LDL. In support of this, data obtained from in vitro 
studies revealed a non-native pentameric CRP, whose LDL-binding recognition functions differs 
from native pentameric CRP (54). 
In the current study, we used a modified CRP, F66A/T76Y/E81A mutant CRP, designed 
by site-directed mutagenesis to mimic the properties of non-native pentameric CRP at 
physiological pH. This mut CRP was tested found to recognize and bind to ox-LDL, one of the 
modified forms of LDL, even in the absence of an acidic environment in a PCh-independent 
manner. Next, we studied the effect of chronic administration of mut CRP on the development 
and progression of atherosclerosis using HFD fed LDLR-/- mice in two independently performed 
experiments. We found that the size of atherosclerotic lesions in the aorta of mut CRP treated 
mice was reduced in comparison to the untreated mice. This effect was observed after 7 weeks of 
mut CRP administration at every alternate day. In addition, we observed that the progression of 
atherosclerosis was halted post 5 weeks of chronic mut CRP administration. The results obtained 
were consistent between the two independently performed experiments even though the disease 
was observed to be more aggressive in the second experiment when compared to the first 
experiment, but still mut CRP was able to take care of it. However, no such effect was observed 
when the extent of atherosclerosis was assessed in the aortic root area except, that, in the first 
experiment chronic mut administration of CRP slowed the progression of the disease but, it 
could not be replicated in the second experiment.  
Such site-specific effects have been observed in various atherosclerotic studies using 
LDLR-/- mouse models wherein experimental manipulations exhibit development of the disease 
differently at different lesion-prone sites of the vasculature (55-59). Specifically, mut CRP was 
shown to be atheroprotective in the whole aorta but neither pro-atherosclerotic nor anti-
 53 
atherosclerotic in the aortic root. There were no region-specific effects observed in the different 
regions of aorta, i.e., aortic arch, thoracic and abdominal regions. Because the disease 
progression was studied in the earlier stages, the lesions formed mostly in the aortic arch area 
and were only sporadically observed in the thoracic aorta. Although the aortic root may provide 
significant information on lesion initiation and progression, its lesion responses are not 
invariably reflective of the lesions throughout the whole aorta. The observed beneficial effects of 
mut CRP on atherosclerosis outside of the aortic root may reflect unknown region-specific 
functions of CRP. Alternatively, it is possible that the ability of mut CRP to retard lesion 
formation is too subtle to overcome the aggressive atherogenesis induced in the aortic root by the 
HFD employed in our study, i.e., the rate of lesion formation in the whole aorta is slower in 
comparison to aortic root and therefore, mut CRP is able to exhibit an observable effect. 
The co-localization of native CRP with macrophages and LDL in atherosclerotic lesions 
in the aortic root has been reported. Modified LDL (ox-LDL, and E-LDL) have been shown to 
induce the formation of foam cells via uptake by macrophages. (5, 60-66). Because in the current 
study, mut CRP showed an atheroprotective effect in the whole aorta, we determined the 
presence of administered mut CRP at atherosclerotic lesion in the whole aorta and we found that 
mut CRP was localized in the en face atherosclerotic lesion. This suggest that mut CRP co-
localizes with LDL at the atherosclerotic lesion in the whole aorta. We hypothesize a mechanism 
for the atheroprotective effect exhibited by mut CRP, where mut CRP recognizes and interacts 
with modified LDL at the atherosclerotic lesions and prevents the formation of foam cells by 
blocking the uptake of LDL by macrophages. This hypothesized mechanism, although yet to be 
studied, is in accordance with a previously published study, where they reported that in vitro 
CRP-bound E-LDL prevents the transformation of macrophages to foam cell (67). The 
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atheroprotective effect of mut CRP in the whole aorta was observed in the absence of any 
observable changes in the plasma lipid (HDL and LDL) concentrations suggesting that mut CRP 
did not bind or had any effect on the lipoproteins in fluid phase. 
As discussed above, the co-localization of CRP with LDL and its deposition in 
atherosclerotic lesions indicates the presence of a structurally altered or non-native CRP at the 
lesions. Interaction of LDL with CRP is mediated through PCh, apolipoprotein B and, 
cholesterol moieties (68-70). The moiety on modified LDL and the binding site on non-native 
pentameric CRP with which this interaction is mediated, is still unknown. One of the possible 
binding sites involved in this interaction might be the inter-subunit contact region in CRP since 
this region is inaccessible in native CRP but accessible in non-native CRP (18, 40). Another 
possible binding site involved in this interaction might be the cholesterol binding sequence 
(amino acid 35 to 47) since it has been found that to mediate the interactions of monomeric CRP 
with diverse ligands (71). In conclusion, non-native pentameric CRP such as in vitro-modified 
CRP (F66A/T76Y/E81A mutant CRP) binds to modified LDL without the requirement of an 
inflammatory microenvironment and shows a site-specific atheroprotective effect by decreasing 
the size of atherosclerotic lesion in the whole aorta post 8 weeks of high fat diet and halted the 
progression of atherosclerosis post 6 weeks of high fat diet. This study provides a proof of 
principle for the ability of a mut CRP to be further described as an atheroprotective molecule. 
Since, this is a single dose-one model regimen, further studies are required to define potential 








1. A triple mutant CRP ( F66A/T76Y/E81A mutant CRP), locked in an alternate pentameric 
structural conformation, binds to oxidized LDL at physiological pH. 
2. Chronic administration of F66A/T76Y/E81A mutant CRP, decreased atherosclerotic 
lesion development and progression in a site-specific manner, wherein it decreased 
atherosclerotic lesion in whole aorta but had no effect in the aortic root. 
3. F66A/T76Y/E81A mutant CRP or CRP in its non-native pentameric conformation is an 
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Abstract 
C-reactive protein (CRP) has been conserved throughout evolution. Human native CRP exhibits 
calcium-dependent binding specificity for phosphocholine. Human CRP in its non-native 
structure expresses the capability to bind to deposited and conformationally-altered proteins, 
which can be achieved by several means including treatment of CRP with acidic pH. The ligand-
binding property of human CRP in its non-native structure has implications for toxic and 
inflammatory conditions and favors the conservation of CRP throughout evolution. It is not 
known, however, whether CRP from invertebrates exhibits structure-based ligand-binding 
properties similar to that of human CRP. The aim of this study was to investigate the ligand-
binding properties of CRP from American horseshoe crab Limulus polyphemus. We used 
different protein ligands immobilized on microtiter plates as a model for deposited and 
conformationally-altered proteins. We found that Limulus CRP binds to immobilized protein 
ligands at physiological pH, in contrast to human CRP which requires acidic pH to do so. The 
binding of Limulus CRP to these immobilized protein ligands occurred even in the absence of 
calcium, suggesting that the binding was not mediated through exposed phosphocholine 
molecules. We conclude that the structure-based ligand recognition function of CRP evolved 
with the development of the immune system to expose a ligand-binding specificity only when 
needed, that is, an inflammatory microenvironment would have to be sensed by CRP and that 
CRP would change its structure to execute its function. Limulus CRP also provides us with a tool 







C-reactive protein (CRP), a member of the short pentraxin family, is a phylogenetically 
conserved protein (1). From arthropods to humans, CRP has been found to be present in every 
organism with similarity in three properties (2-6). First, structurally it is a cyclic oligomer of 
almost identical subunits with subunit molecular weight ranging from 20-30 kDa. Second, it 
recognizes and binds to phosphocholine (PCh) in a calcium-dependent manner and third, it 
exhibits immunological cross-reactivity with human CRP. In humans, CRP is an acute phase 
plasma protein but in some species it acts as a constitutive protein. CRP, from all species have an 
amino acid sequence ranging from 206-218 amino acids, although the sequence homology 
differs between species. Apart from human CRP, the function of CRP in other species is not 
known (7). 
Amongst all species, human CRP is the most studied protein in terms of structure and 
function. CRP is a major acute phase hepatic protein in humans, the concentration of which 
increases more than 1000-fold in acute inflammatory conditions (8). Structurally, human CRP is 
a symmetrical pentamer consisting of five non-covalently attached subunits with an amino acid 
sequence of 206 amino acids. It is a 120 kDa protein with subunit molecular weight of 
approximately 23 kDa. Topologically, every subunit is folded into two anti-parallel beta sheets 
depicting a jellyroll (9-10). Each subunit has a recognition face that consists of a PCh- binding 
site with two coordinated calcium ions. PCh-binding site consists of Phe66, Thr76, and Glu81 
along with residues 134-148 that forms the calcium ion binding site (11-14).  The face opposite 
to the recognition face is the effector face that has been shown to bind to C1q and activate 
complement (15-17). 
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In contrast to human CRP, CRP from the arthropod horseshoe crab (Limulus 
polyphemus), is a constitutively expressed hepatopancreatic, glycosylated protein with a 
concentration of approximately 1-7 mg/ml. It is the most abundant pentraxin followed by SAP-
like pentraxin in the hemolymph (18-19). Structurally, it is a dodecamer consisting of two rings 
of doubly stacked hexagons with an amino acid sequence of 218 amino acids. The molecular 
weight of Limulus CRP is known to be approximately 300 kDa with subunit molecular weight 
ranging between 25-30 kDa. It has been shown to be present in three different polymorphisms 
with variable glycosylation (24-27). It has 25-30% sequence homology with human CRP along 
with conserved protein structure of a jellyroll consisting of two anti-parallel beta sheets (20-26). 
High resolution X-ray crystallographic studies revealed the structural similarity of the PCh- 
binding site between Limulus and human CRP as Phe66, which is one of the amino acids 
involved in forming the PCh-binding site in human CRP, is conserved in Limulus CRP. Residues 
139-153 show sequence homology with residues 134-148 (calcium-ion binding site in human 
CRP) in 9 out of 15 positions providing evidence for the conservation of the calcium ion binding 
site (7,27).  
It has been shown that human CRP, in its native conformation does not have the ability to 
recognize and bind to immobilized, denatured and aggregated proteins. However, when exposed 
to an acidic environment, the native pentameric structure transforms into another pentameric 
configuration which further exposes a hidden ligand-binding site for non-PCh ligands. This 
structural change enables CRP to bind to such aggregated proteins, thus providing a unique 
structure dependent recognition feature to human CRP (28-30). However, it is not known if this 
feature of human CRP has been conserved during evolution. Therefore, the aim of this study was 
to investigate the structure-dependent ligand binding function of Limulus CRP. We found that 
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CRP from an evolutionarily distant species, Limulus polyphemus, can recognize and bind to 
immobilized, denatured and aggregated proteins in its native structural conformation. Therefore, 























Materials and Methods 
Purification of CRP from hemolymph of Limulus polyphemus  
Limulus polyphemus hemolymph (blood; 50 ml) was centrifuged at 15000g for 15 
minutes in order to pellet the cells yielding a clear blue plasma. Limulus plasma was then 
subjected to Sepharose 4B absorption for the removal of carbohydrate binding proteins. 
Approximately 10 ml Sepharose 4B beads (Sigma Aldrich; cat# 4B200) were packed in a 
column and equilibrated with 10 ml of TBS (10 mM Tris + 150 mM NaCl; pH 7.2) + 2 mM 
CaCl2. Limulus plasma was then passed through packed Sepharose 4B beads and the plasma was 
collected. The column was washed with TBS + 2 mM CaCl2 until the blue color disappeared 
from the beads (approximately 10 ml of TBS + 2 mM Ca2+). The plasma was further subjected to 
polyethylene glycol (PEG) treatment for the removal of hemocyanin by adding 3% of PEG 8000 
to the plasma. The treatment with PEG 8000 was carried out on a shaker for 16 hours at 40C. 
Following PEG treatment, plasma was centrifuged at 30000g for 30 minutes and the dark blue 
pellet was discarded leaving a clear, transparent plasma. CRP was isolated from the plasma of 
Limulus polyphemus in a series of three chromatography that included affinity chromatography, 
anion exchange chromatography and HPLC (Gel filtration protein purification system).  
PCh affinity chromatography was performed for purifying PCh-binding Limulus CRP 
(CRP-I), using commercially available PCh-conjugated Sepharose beads (Pierce), as described 
previously (31). Briefly, 1ml PCh-Sepharose beads were packed into a column and equilibrated 
with 10 ml of BBS (0.1M borate-buffered saline; pH 8.3) +3 mM CaCl2 [BBS-Ca]. The clear, 
transparent Limulus plasma obtained after Sepharose absorption, high speed centrifugation and 
PEG treatment was diluted 1:3 with BBS-Ca and passed through the column at a slow flow rate. 
The flow-through from the column was collected and saved to purify further Limulus protein still 
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present in the hemolymph. The column was washed with BBS-Ca and CRP was eluted from the 
column by passing BBS + 5 mM EDTA (BBS-EDTA). 0.5 ml fractions were collected and 
A280 for each fraction was measured. Fractions were collected until the A280 < 0.02. After all 
bound CRP was eluted, fractions containing CRP were pooled and dialyzed against TBS + 2 mM 
CaCl2. PEt-binding Limulus CRP (CRP-II) was purified using phosphoethanolamine (PEt) 
affinity chromatography, as described previously (31). Briefly, 1ml PEt conjugated Sepharose 
beads were packed into a column and equilibrated with 10 ml of BBS-Ca. PEt binding protein 
was purified from PEt-Sepharose column in the manner similar to the one described above for 
purification using PCh-Sepharose column. After purification, CRP-containing fractions were 
dialyzed against TBS + 2 mM CaCl2 and both PCh-binding Limulus CRP (CRP-PCh) and PEt-
binding Limulus CRP (CRP-PEt) were processed for gel filtration chromatography. 
Gel filtration chromatography was performed using Superose 12 (10/300 GL Pharmacia) 
column connected to the BioRad's Biologic Duo Flow Protein Purification System, as described 
previously (31). Briefly, the column was equilibrated with 20 ml of filter-sterilized and degassed 
TBS + 5 mM EDTA at a flow rate of 0.3 ml/min. Concentrated CRP (400 μl) was injected into 
the Superose12 column using a loop and CRP was eluted with TBS + 5 mM EDTA. Fractions 
(0.25 ml) were collected and A280 measured to determine the elution volume of CRP from the 
column. CRP-containing fractions were pooled and dialyzed against TBS+2mM CaCl2. 
Molecular weight determination of Limulus CRP by Gel filtration calibration 
In order to elucidate molecular weight of Limulus CRP (CRP-I and CRP-II), we 
performed gel filtration chromatography, as described above, of three known molecular weight 
proteins [Apoferritin (440 kDa), human CRP (120 kDa) and BSA (66 kDa)]. Limulus CRP (both 
PCh and PEt binding protein) were then subjected to gel filtration purification. Apoferritin, 
 73 
human CRP and BSA were eluted from the column using TBS + 2 mM CaCl2 while Limulus 
CRP was purified using TBS + 5 mM EDTA. A280 of the fractions was measured and the elution 
volume of the protein was determined by the area of the single peak obtained in the purification 
profile. Log molecular weight of the proteins were plotted against elution volume (ml) and based 
on the molecular weight of the standard proteins, the molecular weight of Limulus CRP species 
was determined. 
SDS PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) 
In order to determine purity of Limulus CRP (both CRP-I and CRP-II), a denaturing, 4-
20% gradient gel electrophoresis was performed. A 4-20% resolving gel (30% acrylamide + 
1.5M Tris HCl pH 8.8+ 10% SDS + Glycerol + TEMED + 10% APS+ H20) was prepared using 
a gradient mixer and following its polymerization, 4% stacking gel (30% acrylamide + 0.5M Tris 
HCl pH 6.8+ 10% SDS + TEMED + 10% APS+ H20) was added and allowed to polymerize. 
Protein (10 µg) diluted with 4X sample loading buffer (1M Tris HCl pH 6.8 + 40% glycerol + 
SDS +0.5% Bromophenol blue +b-mercaptoethanol) was loaded and 1X running buffer (3g Tris 
base + 14.4g Glycine + 1g SDS+ H20) was added to the tank. Gel was subjected to 
electrophoresis at 80 volts until protein enters the resolving gel and then, at 150 volts for 5 hours. 
Following electrophoresis, the gel was stained in Coomassie staining solution (45% methanol + 
0.25% Coomassie brilliant blue G250 + 7.5% glacial acetic acid + H20) overnight at room 
temperature and destained (45% methanol + 7.5% glacial acetic acid) until the background was 





Rabbit polyclonal antibodies to preferred Limulus CRP-I were generated commercially 
(Thermofischer). In order to evaluate the binding avidity of anti- Limulus CRP for CRP-I and its 
cross reactivity with CRP-II, ELISA was performed. Briefly, microtiter wells (96 well plate) 
were coated with CRP-I and CRP-II (10 μg/ml-0; two fold serial dilution) and incubated at 370 C 
for 2 hours. The wells were then blocked with TBS containing 0.5% gelatin (Sigma-Aldrich) for 
45 minutes at room temperature. After washing with TBS-Ca (TBS containing 2 mM CaCl2, 
0.1% gelatin, and 0.02% Tween 20), rabbit anti- Limulus CRP Ab, diluted in TBS-Ca (1:500 
dilution), was added to the well and incubated for 1 hour to detect bound CRP. HRP-conjugated 
donkey anti-rabbit IgG, diluted in TBS-Ca (1:1000 dilution), was used as the secondary 
antibody. Color was developed using ABTS as the substrate and the A value was read at 405 nm 
using a microplate spectrophotometer. 
Amino acid sequencing 
Amino acid sequencing of gel filtration purified Limulus CRP (CRP-I and CRP-II) was 
performed by the Molecular Structure Facility, University of California, Davis. 
Protein Ligand Binding Assay 
The protein ligand binding assay was used to determine the binding of Limulus CRP 
(CRP-I and CRP-II) to a variety of immobilized proteins. Factor H (Complement Technology; 
cat# A137), IgG (Sigma-Aldrich; cat # I2511), BSA (Sigma-Aldrich; cat# 05470), amyloid β 
peptide 1–42 (Ab) (Bachem; cat#  4014447), Ac-LDL (acetylated LDL), ox-LDL (oxidized 
LDL), and gelatin (Sigma-Aldrich; cat# G6650) were used as protein ligands. Ac-LDL and ox-
LDL were prepared as described previously (28). Microtiter wells were coated with 10 μg/ml 
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protein ligands diluted in TBS (100 μl/well) and incubated overnight at 4 °C. The unreacted sites 
in the wells were blocked with TBS containing 0.5% gelatin. Limulus CRP I (20 μg/ml-0; two 
fold serial dilution) and Limulus CRP II (40 μg/ml-0; two fold serial dilution) were diluted in 
TBS-Ca (presence of calcium) or TBS-EDTA (TBS containing 5 mM EDTA, 0.1% gelatin, and 
0.02% Tween 20; absence of calcium), added to the wells, and incubated overnight at 4 °C. The 
wells were then washed with the appropriate buffers, TBS-Ca (presence of calcium) or TBS-
EDTA (absence of calcium) prior to the addition of anti- Limulus CRP Ab, diluted in TBS-Ca 
(1:500 dilution) was used to detect bound CRP. After 1 hour, incubation at 37 °C, the wells were 
rinsed again and HRP-conjugated donkey anti-rabbit IgG (GE Healthcare) diluted in TBS-Ca 
was added for 1 h at 37 °C. Color was developed using ABTS as the HRP substrate, and 
the absorbance was read at 405 nm using a microplate reading spectrophotometer. 
Deglycosylation of Limulus CRP 
Deglycosylation of CRP-I and CRP-II was performed using chemical and enzymatic 
methodolgy. Chemical deglycosylation was performed using trifluoromethanesulfonic acid 
(TFMS) (Sigma; cat# 34,781-7) and methodology was followed according to manufacturer’s 
instructions for Glycoprofile IV chemical deglycosylation kit (Sigma; cat # PP0510). Briefly, 
150 µl of chilled TFMS was added to 1 mg of pre-cooled lyophilized Limulus CRP samples and 
incubated for 25 minutes on ice with occasional shaking. Bromophenol blue solution (0.2%; 4 
µl) was added to the reaction followed by dropwise addition of 60% pyridine solution (Sigma; 
cat# P 5496) in a methanol-dry ice bath until the color of the reaction changes from red to light 
purple or blue. The deglycosylated samples (CRP-I and CRP-II) were dialyzed against 1x TBS 
overnight with four changes of buffer. 
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Enzymatic deglycosylation was performed under denaturing and non-denaturing 
conditions using a protein deglycosylation mix II kit (New England Biolabs, cat# P6044) 
according to manufacturer’s instructions. Following deglycosylation, the protein samples were 
dialyzed against TBS for 16 hours at 40C with two changes of buffer. Deglycosylated proteins 
were then subjected to SDS PAGE. The binding activity of deglycosylated Limulus CRP species 
(CRP-I and CRP-II) to immobilized protein ligands at physiological pH was evaluated by an 
ELISA-based assay using Ab was used as the representative protein ligand.  
Data Plotting 
All experiments were performed three times, and comparable results were obtained each 
time. The results of a representative experiment are shown in the figures where the raw data 















Two CRP species with varying affinities for PCh and PEt were isolated from the 
hemolymph of Limulus polyphemus. The gel filtration elution profiles of both CRP- I (PCh-
binding protein) and CRP- II (PEt-binding protein) were similar as both proteins eluted as a 
single peak at the same elution volume and the molecular weight was estimated to be 
approximately 300 kDa (Fig 3.1 A and B). Denaturing SDS PAGE analysis of CRP- I and CRP- 
II revealed two bands of molecular mass 29.5 kDa and 26.9 kDa respectively (Fig 3.1 C). 
Although, both CRP-I and CRP-II contained two bands but, the intensity of the bands differed 
between the two species, with the 26.9 kDa band having similar intensity for both CRP-I and 
CRP-II while the intensity of the 29.5 kDa band was more prominent for CRP-I as compared to 
CRP-II. Another difference between CRP-I and CRP-II was observed during affinity purification 
where CRP-I, eluted either by EDTA or PCh, produced identical bands on denaturing SDS-
PAGE gels while CRP-II eluted by EDTA, contained an additional band (32.3 kDa) that was not 
observed by PEt elution.   
The molecular weight of the protein as determined by gel filtration profile and the 
molecular mass of the subunits for both CRP-I and CRP-II, suggests that it is composed of 12 
subunits, six copies of each subunit stacked together as an oligomer. This result is consistent 
with a previously published study that states the determined molecular weight and subunit 
composition of Limulus CRP (25). Because Limulus CRP is a glycoprotein, the differential 
purification and the intensity of the subunits between CRP-I and CRP-II may be attributed to the 
differential glycosylation patterns on the two CRP species. When the binding affinity for 
antibody (rabbit polyclonal anti-CRP-I) was analyzed for CRP-I and CRP-II, we found that 
rabbit polyclonal anti-CRP-I binds to CRP-II with similar affinity as it does to CRP-I (Fig 3.1 
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D). Further,  purified CRP-I and CRP-II were subjected to amino acid sequencing. The amino 
acid sequence of first ten amino acids of CRP-I was LEEGEITSKV and CRP-II was 
LEEGEITSKI. The amino acid sequence of CRP-I and CRP-II was similar for the first nine 
residues. However, it differed at the tenth residue. Evidence of polymorphism for Limulus CRP 
has been reported, where the amino acid sequence of the different isoforms of Limulus CRP were 

























































































Figure 3.1: Purification and characterization of CRP-I and CRP-II. (A) Gel filtration 
elution profiles of of CRP-I (red) and CRP-II (black) purified from the hemolymph of 
Limulus polyphemus are shown. Molecular weight of CRP-I and CRP-II was determined 
by using gel filtration elution profiles of Apoferritin (440 kDa), human CRP (120 kDa), 
and BSA (66 kDa). Chromatography was performed in TBS, pH 7.2, containing 5 mM 
EDTA. A representative of three chromatograms from the Superose 12 gel filtration 
column is shown. (B) Molecular weight of Limulus CRP-I and CRP-II was determined to 
be 300 kDa. A linear regression plot of (A) is shown, where the molecular weight of 
standards are plotted against their gel filtration elution volume. Limulus CRP-I and CRP-
II (red), based on their gel filtration elution volume, are extrapolated and their molecular 
weight determined.  (C) Coomassie blue-stained SDS-PAGE comparing the pattern of 
proteins present in Limulus CRP purified by either phosphocholine (PCh) or 
phosphoethanolamine (PEt). CRP-I and CRP-II (10 μg) were electrophoresed on a 4–
20% gradient SDS-PAGE gel under denaturing conditions Lanes 1 and 6, molecular 
weight standards. Lanes 2 and 3, CRP-I eluted by EDTA and PCh respectively. Lanes 4 
and 5, CRP-II eluted by EDTA  and PEt respectively. (D) Rabbit polyclonal antibody to 
CRP-I displays cross- reactivity with CRP-II. Enzyme-linked immunosorbent assay 
(ELISA) plates were coated with increasing amounts CRP-I and CRP-II, as indicated. 
The binding of anti-CRP-I antibody was detected using HRP-conjugated donkey anti-
rabbit IgG, a colorimetric substrate, and quantified by measuring the absorbance at 405 
nm using a microplate reading spectrophotometer. 
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The binding of CRP-I and CRP-II to a variety of immobilized protein ligands, such as 
Ab, ox-LDL, Ac-LDL, Factor-H, aggregated IgG (agg IgG), BSA, and gelatin was investigated 
at physiological pH. All ligands were used at a concentration of 10 μg/ml to coat the wells. As 
shown (Fig 3.2 A), CRP-I bound to these immobilized protein ligands in a concentration-
dependent manner, in the following order Aβ > Ac-LDL > ox-LDL > agg-IgG > Factor-H. We 
did not detect binding of CRP-I to either BSA or gelatin. We next sought to determine if calcium 
binding site is critical for CRP-I to recognize and bind to these immobilized ligands by 
performing the experiment in the presence of EDTA (absence of calcium). As shown (Fig 3.2 B), 
the binding curves of CRP-I binding to immobilized ligands are similar to the ones observed 
above, in the presence of calcium (Fig 3.2 A). 
When the binding of CRP-II to immobilized protein ligands was analyzed at 
physiological pH, similar results were obtained as for CRP -I, where CRP-II bound to these 
immobilized protein ligands in a concentration-dependent manner, in the following order Aβ > 
ox-LDL > Ac-LDL > agg-IgG > Factor-H while no binding was observed to either BSA or 
gelatin (Fig 3.2 C). Also, the binding of CRP-II to immobilized protein ligands was also calcium 
independent as it recognized and bound to these immobilized ligands in the absence of calcium 
(Fig 3.2 D). The manner in which CRP-II bound to these immobilized ligands, in the absence of 
calcium was similar as observed in the presence of calcium with the exception of Ac-LDL and 
ox-LDL ( Ac-LDL > ox-LDL). Because both Ac-LDL and ox-LDL are modified versions of 
lipoproteins, the differential binding in the absence of calcium does not correlate with the change 






Figure 3.2: Limulus CRP-I and CRP-II recognizes and binds to immobilized protein 
ligands at physiological pH.  (A and C) For analyzing binding of CRP-I (A) and CRP-II 
(C) to immobilized ligands, microtiter wells were coated with 10 μg/ml of amyloid β 
peptide 1–42 (Ab), ox-LDL, ac-LDL, factor H, aggregated IgG (agg IgG), BSA, and 
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in TBS-Ca were then added to the wells and incubated for 2 hours at 37 °C. Bound CRP 
was detected by using rabbit anti-CRP-I antibody and HRP-conjugated donkey anti-rabbit 
IgG. Color was developed, and the A value was read at 405 nm. A representative of three 
experiments is shown. (B and D)  Representative result for the binding of CRP-I (B) and 
CRP-II (C) to the above mentioned immobilized ligands, in the absence of calcium (TBS-
EDTA), are shown.  
 
These data indicate that both CRP-I and CRP-II have the ability to recognize 
immobilized and conformationally altered, denatured, and aggregated proteins at physiological 
pH. Also, these proteins might be recognizing and binding to amyloid-like like structures that are 
exposed by the protein ligands upon immobilization (30) because as the extent of the exposure of 
these amyloid-like structures after immobilization decreases (Aβ < ox-LDL < Ac-LDL < agg 
IgG < Factor-H < BSA < gelatin), the ability of CRP-I and CRP-II to recognize them and bind to 
them also decreases. Also, this binding is calcium independent and calcium binding site doesn’t 
play a role in recognition of conformationally altered, denatured, and aggregated proteins by 
CRP-I and CRP-II. 
Both species of Limulus CRP, CRP-I and CRP-II, are glycosylated proteins, unlike 
human CRP (25, 26). In order to investigate the role of carbohydrate moieties present on CRP-I 
and CRP-II, we subjected both proteins to chemical and enzymatic deglycosylation. Denaturing 
SDS PAGE analysis of CRP-I following enzymatic deglycosylation (deglycosylation performed 
under denaturing and non-denaturing conditions), revealed no alteration in the mobility of either 
of the two bands. However, when CRP-I was subjected to chemical deglycosylation, only one 
band of molecular mass 23.2 kDa was observed (Fig 3.3 A). In comparison, enzymatic 
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deglycosylation of CRP-II, altered (reduced) the intensity of the 29.5 kDa band. Chemical 
deglycosylation of CRP-II affected the mobility of the observed three bands resulting in two 
bands of molecular mass 26 kDa and 23.2 kDa, respectively (Fig 3.3 C). Although, three bands 
were observed in denaturing SDS-PAGE analysis of native CRP-II, anti-CRP-I antibody 
recognized only two bands of molecular mass 29.5 kDa and 26.9 kDa, respectively (data not 
shown). Thus, the deglycosylated band of 26 kDa observed post chemical deglycosylation of 
CRP-II could either be a deglycoylsylated product of the non-specific 32.3 kDa band or could be 
a result of partial deglycosylation. While we could fully deglycosylate CRP-I and CRP-II, it 
could not be evaluated in functional assays since deglycosylation by chemical and enzymatic 
(under denaturing conditions) methodology rendered the protein in a non-native state (confirmed 
by ELISA; data not shown). 
Although, enzymatic deglycosylation (performed under non-denaturing conditions), did 
not produce a shift in the mobility of CRP-I and CRP-II bands in a denaturing SDS-PAGE, we 
wanted to determine any differences in the functional binding between native and deglycosyated 
state of Limulus CRP species. Because there lies a possibility that the protein was partially 
deglycosyated but there was no noticeable change in the SDS-PAGE band pattern. This might be 
explained in lieu of the extent of glycosylation on these proteins, as they are not fully known. 
Therefore, we compared the functional binding activity of native and deglycosylated CRP-I and 
CRP-II to an immobilized protein ligand, Aβ. As shown (Fig 3.3 B), native CRP-I bound to Aβ 
in a CRP concentration dependent manner. However, enzymatically deglycosylated CRP-I bound 
to Aβ with approximately 100-fold less avidity when compared to native CRP-I. Similar results 





Figure 3.3: Deglycosylation of CRP-I and CRP-II reduces binding to immobilized 
amyloid β peptide 1–42: (A) CRP-I was deglycosylated using chemical, enzymatic 
(under denaturing), and enzymatic (under non- denaturing) means. Native CRP-I (10 μg) 
and deglycosylated CRP-I (10 μg) were subjected to SDS-PAGE under reducing 
conditions in a 4–20% gradient gel. A representative Coomassie Blue-stained gel is 







































shown; lane 1: molecular weight marker, lane 2: Native CRP-I, lane 3: Chemically 
deglycosylated CRP-I, lane 4: Enzymatically (under denaturing conditions) 
deglycosylated CRP-I, and lane 5: Enzymatically (under non-denaturing conditions) 
deglycosylated CRP-I. (B) Microtiter wells were coated with amyloid β peptide 1–42 (10 
μg/ml). The unreacted sites in the wells were blocked with gelatin. Native CRP-I (black) 
and enzymatically (under non-denaturing conditions) deglycosylated CRP-I (red) (both; 
0-40 μg/ml) diluted in TBS-Ca were added to the wells and incubated for 2 hours at 37 
°C. Bound CRP was detected by using rabbit anti-CRP-I antibody and HRP-conjugated 
donkey anti-rabbit IgG. Color was developed, and the A value was read at 405 nm. A 
representative of three experiments is shown. (C) CRP-II was deglycosylated using 
chemical, enzymatic (under denaturing), and enzymatic (under non- denaturing) means. 
Native CRP-II (10 μg) and deglycosylated CRP-II (10 μg) were subjected to SDS-PAGE 
under reducing conditions in a 4–20% gradient gel. A representative Coomassie Blue-
stained gel is shown; lane 1: Native CRP-II, lane 2: Chemically deglycosylated CRP-II, 
lane 3: enzymatically (under denaturing conditions) deglycosylated CRP-II, lane 4: 
enzymatically (under non-denaturing conditions) deglycosylated CRP-II, and lane 5: 
molecular weight marker. (D) Microtiter wells were coated with amyloid β peptide 1–42 
(10 μg/ml). The unreacted sites in the wells were blocked with gelatin. Native CRP-II 
(black) and enzymatically (under non-denaturing conditions) deglycosylated CRP-II (red) 
(both; 0-40 μg/ml) diluted in TBS-Ca were added to the wells and incubated for 2 hours 
at 37 °C. Bound CRP was detected by using rabbit anti-CRP-I antibody and HRP-
conjugated donkey anti-rabbit IgG. Color was developed, and the A value was read at 405 
nm. A representative of three experiments is shown. 
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These data indicated that the presence of carbohydrate moieties on CRP-I and CRP-II 
plays a role in its ability to recognize and bind to conformationally altered, denatured, and 
aggregated proteins since, removal of these moieties leads to loss of these protein’s ability to 






















A SAP-like pentraxin has been shown to be present in the hemolymph of Limulus 
polyphemus along with CRP (34). As opposed to Limulus CRP which has an affinity for PCh and 
PEt, Limulus SAP-like pentraxin has an affinity for PEt and carbohydrate moieties but not PCh. 
Therefore, we pre-absorbed the SAP-like pentraxins from hemolymph by using Sepharose-
affinity chromatography prior to purifying CRP. We then purified CRP by two means, PCh 
dependent affinity chromatography and PEt dependent affinity chromatography and investigated 
the ligand recognition function of Limulus CRP. Our major findings were as follows: 1) Limulus 
CRP is a 300 kDa protein that exists as a dodecamer with two rings of six subunits each, as 
published previously (25); 2) The differential glycosylation patterns on Limulus CRP might be 
playing a role in its differential affinity for PCh and PEt; 3) Limulus CRP can recognize and bind 
to immobilized, denatured, and aggregated proteins in a calcium independent manner, at 
physiological pH; and 4) The ligand recognition function of Limulus CRP is dependent on its 
carbohydrate moieties since partial enzymatic deglycosylation greatly affected its ligand binding 
properties. 
American horseshoe crab, Limulus polyphemus, is an evolutionarily distant species the 
origin of which dates back to 300-500 million years. Amongst the entire taxa of arthropods, this 
is the only species in which CRP along with other pentraxins has been identified as the vertebrate 
pentraxins counterpart (18). Along with hemocyanin and a2- macroglobulin, pentraxins are the 
third most abundant proteins present in the hemolymph of these arthropods (34-35). The two 
major pentraxins are CRP (constituting about 80% of pentraxin population) and SAP-like 
pentraxins (constituting about 8-19% of pentraxin population). The N-terminal amino acid 
sequence differs significantly between CRP and SAP-like pentraxin along with the affinity for 
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ligands. CRP has an affinity for PCh and PEt but not carbohydrate moieties while SAP-like 
pentraxins has an affinity for PEt and carbohydrate moieties but not PCh (18-19). A third 
pentraxin, limulin (approximately 1% of pentraxin population), was also identified in the 
hemolymph of these animals. Initially, limulin and Limulus CRP were considered to be the same 
because of identical N terminal amino acid sequence. However, it was later on shown that 
though closely related, the two proteins are unique with differences in their ligand affinity. CRP 
has an affinity for PCh and PEt but not sialic acid while limulin has an affinity for PCh, PEt, and 
sialic acid (20-21, 37-40). In our study, we purified two different isoforms of Limulus CRP with 
differences in their ligand affinity for PCh and PEt. Since, our protein of interest was CRP, 
passage of hemolymph over Sepharose column eliminated SAP-like pentraxin. Also, neither of 
the two isoforms of Limulus CRP, CRP-I and CRP-II are likely to be limulin because when both 
CRP isoforms were passed over fetuin-sepharose column (sialic acid affinity chromatography), 
none of them bound to the column (data not shown). 
CRP is present in the hemolymph of Limulus polyphemus in a wide concentration range 
of 0.2-6 mg/ml (25). We purified CRP-I at a concentration of 0.2 mg/ml and CRP-II at a 
concentration of 0.006 mg/ml. We observed that the affinity of Limulus CRP for PCh-sepharose 
is about 5 mg/ml beads in contrast to human CRP whose affinity is over 10 mg/ml beads which 
is consistent with a previously reported study (37). In contrast, the affinity of Limulus CRP for 
PEt-sepharose is about 2 mg/ml beads, which is consistent with the behavior of human CRP as 
human CRP has much higher affinity for PCh-sepharose as compared to PEt-sepharose (25). The 
lower affinity of Limulus CRP for PCh-sepharose in comparison to human CRP could be 
attributed to its higher molecular weight that can limit its access to the PCh moieties when 
complexed with Sepharose. Limulus CRP, purified by PCh affinity chromatography (CRP-I) and 
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PEt affinity chromatography (CRP-II), is a high molecular weight protein with estimated 
molecular weight of 300 kDa organized as double stacked, identical hexameric assembly 
(dodecamer) (22-23). Each subunit molecular mass was estimated as 26-32 kDa. As opposed to 
human CRP that exists in mammalian circulation as a non-glycosylated protein, Limulus CRP 
has been known to exist in three different polymorphisms with differences attributed to the 
glycosylation pattern as these three polymorphisms share similar amino acid sequencing with 
only 10 % microheterogeniety amongst them (23-27). The N terminal amino acid sequencing of 
CRP-I and CRP-II were similar (Leu-Glu-Glu-Gly-Glu-Gly-Ile-Thr-Ser-Lys-Val), suggesting 
that the differential glycosylation of the two CRP’s contributes to their  variable affinity for PCh 
and PEt. Limulus CRP subunits are glycosylated by a single oligosaccharide chain of 
composition Man2GlcNAc2 (differential glycosylations of Man3GlcNAc2, Man4GlcNAc2, or 
Man5GlcNAc2) (26). The difference in the mannose chains in the CRP subunits gives differential 
intensity to the bands in SDS PAGE for CRP-I and CRP-II (two bands of molecular mass 26.9 
kDa and 29.5)  
Human CRP has been shown to be present in two structural configurations: a native 
pentameric CRP at physiological pH that does not recognize immobilized, denatured and 
aggregated proteins and a non-native pentameric CRP at acidic pH that can recognize and bind to 
immobilized, denatured and aggregated proteins (29). In order to determine if this structure-
based ligand binding property of human CRP is inherent in Limulus CRP, we performed ligand 
binding assays. We found that unlike human CRP, Limulus CRP in its native structural 
configuration at physiological pH can recognize and bind to immobilized, denatured and 
aggregated proteins. Both CRP-I and CRP-II does not need any structural modification to gain 
the ligand binding property of non-native pentameric human CRP. However, upon exposure to 
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an acidic environment, both CRP-I and CRP-II recognized and bound to immobilized, denatured 
and aggregated proteins more efficiently than it did at physiological pH (data not shown). The 
functional ligand binding ability of CRP-I and CRP-II at both physiological and acidic pH might 
provide protection against enhanced protein toxicity in these arthropods, as they are constantly 
being exposed to harsh environments. Non-native human CRP has an exposed ligand binding site 
that can recognize and bind non-PCh containing ligands (immobilized, denatured and aggregated 
proteins) in a calcium-independent manner. This property of non-native human CRP is consistent 
with native Limulus CRP, as it also recognizes and binds to immobilized ligands in the presence 
and absence of calcium. This ligand binding property of Limulus CRP in the absence of calcium 
further suggests that it does not bind to the PCh moieties , if exposed, on these ligands as 
presence of calcium is critical for PCh-binding. The pattern of CRP-I and CRP-II binding to 
immobilized ligands suggests that it recognizes and bind to amyloidogenic-like structures 
expressed by the proteins upon immobilization as it binds more efficiently to Ab  compared to 
factor-H and doesn’t bind at all to BSA and gelatin. 
Over the course of evolution, the glycosylation patterns on CRP have changed, where 
Limulus CRP-I and CRP-II are glycosylated while human CRP is non-glycosylated. Human CRP 
does possess sites of glycosylation but they are hidden in its native conformation and therefore 
may provide no functional advantage to native CRP (41-43). In order to determine if the 
glycosylated moieties have any role in the structure-ligand function of Limulus CRP, we de-
glycosylated CRP-I and CRP-II and observed that the ability of the deglycosylated CRP-I and 
CRP-II, to recognize and bind to immobilized, denatured and aggregated proteins was greatly 
decreased (approximately 100 fold) when compared to their glycosylated counterparts. 
 91 
Therefore, native glycosylated Limulus CRP displays similar ligand binding function as non-
native human pentameric CRP. 
An innate immune system has a pivotal role in host-defense mechanism where its major 
function is identification of pathogens and its clearance or inactivation. The innate immune 
system is unique in these arthropods as they have complement-like activity but without the 
acquired immunoglobulin‐dependent immunity that is present in vertebrates. Hence, the immune 
system evolved from these ancient species, where a2- macroglobulin and pentraxins exhibit the 
function of immune defense proteins using cytolysis for pathogen elimination, to humans where 
this function is taken over by acute phase reactants and complement activation (18). As the 
immune system evolved, the nature of CRP gene expression also evolved from a constitutively 
expressed protein in Limulus polyphemus to an acute phase protein in humans. 
We conclude that though the ligand-binding properties of Limulus CRP are not identical 
to that of native human CRP, they overlap the ligand-binding properties of non-native 
pentameric human CRP that can be generated at inflammatory microenvironments. Also, 
changing the glycosylation state of Limulus CRP, changes its ligand-binding and overlapping 
with native human CRP. This suggests that CRP evolved as a component of and along with the 
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Abbreviations: 
CRP                          C-reactive protein 
PCh                           Phosphocholine 
PEt                            Phosphoethanolamine 
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Ox-LDL                   Oxidized low-density lipoprotein 
Ac-LDL                   Acetylated low-density lipoprotein 
TFMS                      Trifluoromethanesulfonicacid 
TBS-Ca                     TBS, pH 7.2, containing 0.1% gelatin, 0.02% Tween 20 and 2 mM CaCl2 
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Gene expression regulation of C-reactive protein (CRP) occurs at transcriptional level by various 
cytokine inducible and constitutively active transcription factors. IL-6 is the major cytokine that 
is known to induce CRP expression by activation of transcription factors STAT3 and C/EBPb. 
The proximal 157 bp region of the CRP promoter has been shown to be sufficient to induce CRP 
transcription in response to IL-6 and binding sites for both these transcription factors are present 
within the -157 bp region of CRP promoter. It has been previously reported that the proximal 
300 bp region of the CRP promoter elicits a higher IL-6 response compared to the 157 bp region. 
An additional C/EBPb site has been shown to be present at position -222, but additional binding 
sites for STAT3 have not been located between -157 to -300 bp region. In the current study, we 
discovered multiple putative IL-6 inducible STAT3 binding sites, located at position -72, -134, 
and -165 respectively, in addition to the previously reported transcriptionally active STAT3 site 
at -108. We found that, although STAT3 binds to its cognate site at positions -134 and -165, the 
STAT3 binding site at -134 is transcriptionally active, unlike -165. The STAT3 site at position -
134 does not activate CRP transcription but rather regulates the gene expression of CRP. We 
hypothesize that IL-6 inducible STAT3 binding sites at position -134 and -108 act co-operatively 
with each other to activate CRP transcription wherein STAT3 (-134) regulates a crosstalk 








C-reactive protein (CRP) is an acute phase protein of the innate immune response of 
humans, serum concentration of which increases significantly followed by either a chronic or an 
acute inflammatory insult (1-6). It is a multifunctional, host defense protein that is produced by 
hepatocytes (7,8). The regulation of CRP synthesis occurs at transcriptional level wherein 
cytokines such as interleukin 6 (IL-6) and interleukin 1b (IL-1b) induce CRP expression via 
activation of various transcription factors (9,10). IL-6, alone or in synergy with IL-1b, actuates 
CRP transcription by activating C/EBP (CCAAT/enhancer-binding protein) family of 
transcription factors and STAT (signal transducers and activators of transcription) family 
members. IL-1b alone does not activate CRP transcription but it does so in synergy with IL-6 via 
activation of nuclear factor kappaB (NF-kB) (8, 11-17). Cytokine (IL-6 + IL-1b)-induced CRP 
transcription has been observed in human hepatoma cell line Hep3B while IL-6 activated 
transcription factors have been shown to induce CRP expression in other hepatic cell lines as 
well (11, 14-16, 18).  
The proximal 157 bp region of the CRP promoter (-157/+1) has been shown to be 
sufficient for inducing CRP transcription in response to IL-6 as IL-6 activated transcription 
factors such as C/EBPb and STAT3 have binding sites on the CRP promoter, centered at position 
-52 and -108, respectively (9,13). Also, IL-1b activated transcription factor, NF-kB binds to its 
site located at position -69 on CRP promoter (Fig 1A). NF-kB regulates CRP transcription via 
formation of homodimers or heterodimers of five NF-kB proteins namely p50, p52, p65, c-Rel, 
and c-Rel B (8). In addition to the cytokine activated transcription factors, other constitutively 
active transcription factors such as C/EBPz, RBP-Jk, Oct-1, HNF-1, and HNF-3 have been 
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shown to regulate CRP gene expression (7,12,19). 
STAT3, one of the STAT family members, transitions from a non-active cytoplasmic 
non-phosphorylated monomeric state to an active nuclear tyrosine-phosphorylated dimeric state. 
This transition is initiated by IL-6 binding to its receptor complex that initiates a pathway of 
Janus kinase kinases phosphorylation with subsequent phosphorylation, dimerization, and 
nuclear translocation of STAT3 (20,21). STAT3 has been shown to bind to acute phase response 
elements on the promoter regions containing TT(N)4AA or TT(N)5AA motifs specifically (22-
24). One such IL-6 induced STAT3 response element, centered at position -108 on the proximal 
human CRP promoter containing the sequence TTCCCGAA,  has been shown to induce CRP 
transcription (13).  
It has been previously reported that the proximal 300 bp region of the CRP promoter (-
300/+3) elicits a higher IL-6 response when compared to the 157 bp region. In addition to the IL-
6 induced transcriptionally active C/EBPb site positioned at -52, another C/EBPb site has been 
shown to be present at position -222. However, additional binding sites for STAT3 are not 
known between -157 bp to -300 bp region. In the current study, the aim was to locate putative 
IL-6 responsive STAT3 binding sites in the -300 bp region of CRP promoter and if located, 
determine whether these sites are transcriptionally active. We revisited the -300/+3 region of 
CRP promoter and found three additional, putative STAT3 binding sites centered at position -72, 
-134, - 165 along with the previously reported STAT3 site at position -108. Our data indicates 
that, in addition to the STAT3 site at position -108, STAT3 binds to IL-6 responsive STAT3 
binding sites located at position -134 and -165, but only the STAT3 site at -134 is 
transcriptionally active. Also, STAT3 site at -134 does not activate CRP transcription but rather 
regulates CRP expression via facilitating crosstalk between other transcription factors. 
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Experimental Procedures 
Identification of putative STAT3-binding sites in -300 bp region of the CRP promoter 
Putative STAT3- binding sites were identified by visual inspection of the proximal 300 
bp region of the CRP promoter. TT(N)4AA or TT(N)5AA containing motifs were considered 
potemtial STAT3-binding regions. 
Preparation of Nuclear Extract and EMSA (Electrophoretic mobility gel shift assay) 
Hep3B cells were used as the source of nuclear extracts. Cells were cultured in a 100 mm 
dish using RPMI media (containing 10% FBS and 1% Penicillin-Streptomycin stock) and at 60% 
confluency, were subjected to serum starvation overnight. Post overnight serum starvation, 
cytokine treatment was performed using IL-6 and IL-6 + IL-1b, for 15 minutes. IL-6 and IL-1β 
(R & D systems; cat# 206-IL and 201-LB, respectively) were used at concentrations of 10 ng/ml 
and 1 ng/ml, respectively. Nuclear extracts were prepared using NE-PER nuclear and 
cytoplasmic kit (Pierce; cat# 78835), as described previously (25). Putative STAT3-containing 
oligonucleotide (oligo) sequences that are used in EMSA are shown in Figure 1B. Oligos were 
obtained from Integrated DNA Technologies. Probes were prepared by annealing 
complementary oligos, followed by labelling with [g 32P] ATP (MP Biomedicals; SKU 
013502005) using end labelling with T4 Polynucleotide kinase ( Promega; M4101). Probe-
nuclear extract reaction mixture was incubated in gel shift incubation buffer (40 mM KCl, 20 
mM Hepes pH 7.9, 1 mM MgCl2, 0.05 mM EGTA, 0.5 mM dithiothrietol, 4% Ficoll, and 1 μg of 
poly dI-dC) for 20 minutes at room temperature. For supershift experiments, antibody to STAT3 
(F20X, Santa Cruz Biotechnologies) was added to the nuclear extract, prior to addition of the 
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probe. DNA- protein complexes were resolved in 5% polyacrylamide native gels containing 
2.5% glycerol and analyzed in a phosphorimager using ImageQuant software (GE Healthcare).  
 
CRP Promoter-Luciferase (Luc) Reporter Constructs 
The engineering of Luc-157 (−157/+1 of CRP gene and Luc-300 (-300/+3 of CRP 
promoter) wild-type (WT) constructs, have been described previously (8,25,28). The WT 
constructs were used as templates for mutagenesis. Constructs containing mutated STAT3 sites 
were generated using the QuickChange site-directed mutagenesis kit (Stratagene) on both Luc-
157 WT and Luc-300 WT. The STAT3-site (-108) was mutated by substituting -111TCCCGA-106 
with -111GATATC-106 using mutagenic primers 5'- 
GCTTCCCCTCTGATATCAGCTCTGACACCTG and 5'- 
CAGGTGTCAGAGCTGATATCAGAGGGGAAGC. The STAT3-site (-134) was mutated by 
substituting -138TTCTGAAA-131 with -138TCCGGCCA-131 using mutagenic primers: 5'- 
TCACATTGATTTCTCTGTCCGGCCATAATTTTGCTTCCCC and 5'- 
GGGGAAGCAAAATTATGGCCGGACAGAGAAATCAATGTGA. The STAT3-site (-165) 
was mutated by substituting -169TTGTAATAA-161 with -169TTCGCAGTA-161 using mutagenic 
primers 5'- 
GGTAATTCAGTAGTCATAGGAGTTCGCAGTACATAACTCACATTGATTTCTCTG and 5'- 
CAGAGAAATCAATGTGAGTTATGTACTGCGAACTCCTATGACTACTGAATTACC. A 
double STAT3 mutant with both -108 and -134 site mutated was generated by using Luc- 157 
mut STAT3 (-108) and Luc- 300 mut STAT3 (-108) as the template and STAT3-site (-134) 
mutagenic primers, as described above. Double STAT3 mutant with both -108 and -165 site 
mutated was generated by using Luc- 300 mut STAT3 (-108) as the template and STAT3-site (-
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165) mutagenic primers, as described above. Plasmids were purified using maxiprep plasmid 
isolation kit (Eppendorf) and mutations were verified by sequencing at the Molecular Biology 
Core Facility at ETSU, 
 
Luciferase (Luc) Transactivation Assay 
Hep3B cells were cultured overnight for transfection and cytokine treatment using serum-
free medium as described previously (26). The confluency of cells at the time of transfection was 
approximately 60%. Cells were plated into 6-well plates for transient transfections, and 
transfection was carried out using FuGENE 6 reagent (Promega). Briefly, per well, 10 µl 
FuGENE 6 was added to 125 µl RPMI-1640 and incubated for 5 minutes. Further, 1µg of 
Luciferase reporter-CRP promoter construct was added to the RPMI- FuGENE 6 cocktail, 
incubated for 20 minutes at RT and added to the well. Cytokine treatment was performed 16 
hours post-transfection. IL-6 and IL-1β (R & D systems) were used at concentrations of 10 ng/ml 
and 1 ng/ml, respectively, and incubation continued for 24 hours. Post-transfection (40 hours) 
and post-cytokine treatment (24 hours), luciferase assays were performed (Luciferase assay 
system with reporter lysis buffer; Promega) as described previously (27). Luciferase activity was 
measured in a luminometer (Molecular Devices), which was programmed for the integration 
time of 10 s with no post-injection delay time. Results were projected as mean ± SD of three 







Multiple IL-6 inducible putative STAT3-binding sites are located within the first 300 bp (-
300/+3) region of CRP promoter  
We examined the proximal 300 bp region of the CRP promoter and located three 
previously undescribed, putative STAT3-binding sites containing TT(N)4AA or TT(N)5AA 
motifs. Two sites were located downstream of -157/+1 region of the CRP promoter, at -72 (-76/-
69: TTGGAAAA) and -134 (-138/-131: TTCTGAAA), while one was located upstream at -165 
(-169/-161: TTGTAATAA) in the -300/+3 region (Fig 4.1 A). 
 
 













Oligo 1 [ STAT3 (-72) ]                       -92  5’ GCCCCAACAAGCAATGTTGGAAAATTATTTACATAGTGCG  3’ -53
GCGCACTATGTAAATAATTTTCCAACATTGCTTGTTGGGG
Oligo 2 [ STAT3 (-134) ]                   -154  5’ GCGCGTGATTTCTCTGTTCTGAAATAATTTTTGCTGCGTG  3’ -115
GCACGCAGCAAAAATTATTTCAGAACAGAGAAATCACGCG
Oligo 3 [ STAT3 (-165) ]                   -182  5’ GGCGCATAGGAGTTTGTAATAAATAACTCACCGC  3’  -149   
GGCGGTGAGTTATTTATTACAAACTCCTATGCGC
Oligos used to construct mutated STAT Luc promoter:
WT TTCCCGAA
mSTAT (-108)                 5’ GCTTCCCCTCTGATATCAGCTCTGACACCTG  3’ 
CAGGTGTCAGAGCTGATATCAGAGGGGAAGC
WT                                                                 TTCTGAAA
mSTAT (-134)                  5’ TCACATTGATTTCTCTGTCCGGCCATAATTTTGCTTCCCC  3’ 
GGGGAAGCAAAATTATGGCCGGACAGAGAAATCAATGTGA 
WT                                                                               TTGTAATAA        




Figure 4.1: The −300 / +3 region of the CRP gene promoter and the sequences of the 
oligos used in this study. (A) The putative binding sites for STAT3 on the CRP promoter 
are shown along with the previously known STAT3 binding site at -108. (B) Sequence of 
the oligos used as probes in EMSA and to construct mutated STAT promoter for 
luciferase assays. Putative STAT3 binding sites are shown, highlighted in blue. Mutated 
nucleotides are indicated in red. 
 
IL-6 activated STAT3 binds to its cognate site at position -134 and -165 on CRP promoter 
Binding of STAT3 to the newly identified putative STAT3-binding sites on the CRP 
promoter was analyzed by EMSA. Nuclear extracts from Hep3B cells treated with IL-6 alone 
and (IL-6 + IL-1b; 15 minutes) were used as source of activated STAT3. Wild- type (WT) 
oligos, containing putative STAT3 sites (-72, -134, and -165), are shown in Fig 4.1 B. When WT 
oligo (-72) was used as probe, several complexes were observed (Fig 4.2 A), however, none 
were clearly abolished or super-shifted by inclusion of anti-STAT3 antibodies. Two STAT3-
containing complexes were observed with WT oligo (-134) as probe (Fig 4.2 B). The intensity of 
the two bands was greater using nuclear extracts from (IL-6 + IL-1b)-treated Hep3B cells 
compared to nuclear extracts from cells treated with IL-6 alone. Using nuclear extracts from  IL-
6 treated cells, only one band (complex II) was clearly visible (Fig 4.2 B, lane2), which was 
supershifted by anti-STAT3 antibody (Fig 4.2 B, lane 4). Nuclear extracts from (IL-6 + IL-1b)-
treated cells, produced two bands ( Complex I and complex II) (Fig 4.2 B, lane3) both of which 
were abolished in the presence of anti- STAT3 antibody (Fig 4.2 B, lane 5). EMSA revealed one 
STAT3-containing complex formed with WT oligo (-165) with nuclear extracts from both IL-6 
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(Fig 4.2 C, lane 2) and (IL-6 + IL-1b) (Fig 4.2 C, lane 3) treated cells. Although the intensity of 
the EMSA bands observed with WT oligo (-165) was not as intense as those observed with WT 
oligo (-134) and WT oligo (-72), they were abolished in the presence of anti- STAT3 antibody 
(Fig 4.2 C, lane 4 and 5 respectively). The abolition of complexes by anti-STAT3 antibodies 
observed with WT oligo (-134) and WT oligo (-165) confirms that these complexes contain 
STAT3. Therefore, out of the identified, putative STAT3 binding sites, STAT3 was shown to 
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Figure 4.2: STAT3 binds to its cognate position at -134 and -165. A representative 
EMSA demonstrating the binding of STAT3 to its putative binding sites on the CRP 
promoter is shown. Radiolabeled WT oligos [ (A) Oligo 1: -72 (-92/-55), (B) Oligo 2: -
134 (-154/-115), and  (C) oligo 3: -165 (-182/-149) ] were used as  probe and nuclear 
extract derived from cytokine (IL-6 and IL-6 + IL-β; 15 minutes)-treated Hep3B cells 
were used as the source of STAT3. Anti-STAT3 was added to nuclear extracts before the 
addition of the probe. DNA probe–protein complexes were visualized using a 
phosphorimager. Complexes containing STAT3 are indicated by arrows and free probe 
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The proximal 157bp region of the CRP promoter is sufficient for transactivation but -300/+3 
region elicits a greater response  
The proximal 157 bp region of CRP promoter has been shown to be sufficient for 
synergistic induction of CRP gene expression. We compared the transactivation of CRP gene 
expression between the proximal 157 bp (Luc 157-WT) and 300 bp (Luc 300-WT) region of 
CRP promoter by Luciferase transactivation assays (Fig 4.3 A). The synergy between IL-6 and 
IL-1b was observed with both Luc-157 WT and Luc-300 WT, with the CRP expression being 
~90 % greater  (*; p = 0.004) in cells treated with (IL-6 + IL-1b) as compared to cells treated 
with IL-6 alone. IL-1b-treated cells displayed similar transactivation as basal (data not shown). 
In all cells treated with IL-6 alone and in cells treated with (IL-6 + IL-1b), Luc-300-WT 
displayed a greater transactivation that Luc-157 WT [~53%  and ~33% (*) respectively]. These 






Figure 4.3: The -300/+3 region of CRP promoter elicits a greater cytokine-induced 
response when compared to the proximal 157 region and the STAT3 site at -108 is 
critical for CRP transcription. (A) Luciferase transactivation assay of Hep3B transfected 
with Luc-157 WT and Luc-300 WT CRP promoter constructs is shown. ((B-D) 
Luciferase transactivation assay showing the effect of mutated STAT3 site at -108 on 
cytokine (IL-6 and IL-6 + IL-1β)-induced CRP expression, is shown. Hep3B cells were 
transfected with Luc-157 WT and Luc-157 mS (-108) (B), Luc-300 WT and Luc-300 mS 
(-108) (C), and Luc-157 mS (-108) and Luc-300 mS (-108) (D) CRP promoter constructs, 
24 h post cytokine treatment and 40 h post transfection, CRP transcription was measured 
as Luc activity. Fold change over basal luciferase activity is plotted on the x-axis. Results 
are expressed as mean ± SD for three experiments. p value of < 0.05 are considered 
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Role of STAT3-site positioned at -134 in IL-6 and (IL-6 + IL1-b)- induced CRP expression 
The binding of STAT3 to its transcriptionally active site at -108 has been well 
documented (13) and as shown in Fig 4.3 B and 4.3 C, mutation of STAT3 (-108) leads to 
reduced IL-6  and  (IL-6 + IL-1b) induced gene expression in both proximal 157 and 300 bp 
region of CRP promoter. However, mutation of STAT3 (-108) in the proximal 300 bp region did 
not completely abolish the activation of CRP expression by IL-6, unlike the proximal 157 bp 
region (Fig 4.3 D). 
To investigate the role of potential STAT3 binding site at -134, in regulating cytokine 
[IL-6 and (IL-6 + IL1-b)] induced CRP expression, we performed Luciferase transactivation 
assays using Luc 157-WT, Luc 300-WT, Luc 157-mS (-134), and Luc 300-mS (-134) promoter 
constructs. In addition, CRP promoter constructs with mutation in both (-108 and -134) STAT3 
sites [Luc-157 mS (-108) + (-134) and  Luc-300 mS (-108) + (-134)], were used to analyze the 
combined function of of STAT3 on CRP promoter activity in response to IL-1b, IL-6, and (IL-6 
+ IL-1b) induced CRP expression respectively. Treatment with IL-1b alone did not induce CRP 
expression above basal levels (data not shown). Mutation of STAT3 (-134) in the 157 bp region 
of CRP promoter, Luc-157 mS (-134) has no effect on (IL-6 + IL-1b)- induced CRP expression 
while the IL-6 induced CRP expression was ~47 % higher (*; p = 0.04) compared to Luc-157 
WT  (Fig 4.4 A). However, mutation of STAT3 (-134) in the 300 bp region, Luc-300 mS (-134) 
resulted in greater IL-6 and (IL-6 + IL1-b) -induced CRP expression (~88% and ~40% (*),  
respectively) (Fig 4.4 B). Consistent with results for mutation of STAT3 (-108), mutating 
STAT3 (-134) in the proximal 300 bp region of CRP promoter produced a higher CRP 
expression as compared to the same mutation in the proximal 157 bp promoter region (Fig 4.4 
C). 
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       Mutation of both STAT3 sites (-108 and -134), Luc-300 mS (-108) + (-134) completely 
eliminated IL-6 and (IL-6 + IL1-b)-induced CRP expression when compared to Luc 300-WT 
(Fig 4.4 E). However, mutation of both STAT3 sites in the 157 bp region, Luc-157 mS (-108) + 
(-134) induced ~49% lower (*) (IL-6 + IL-1b)- induced CRP expression compared WT and no 
effect was observed in IL-6-induced CRP expression (Fig 4.4 E). Mutation of STAT3 sites at -
108 and -134 in the proximal 300 bp region of the promoter lead to loss of the cytokine-induced 
CRP expression, however, the cytokine-induced CRP expression was observed in the 157 bp 
promoter region with both STAT3 sites mutated (Fig 4.4F).  
As reported previously (13) and shown here, the STAT3 (-108) site is involved in 
activating CRP transcription as its mutation reduced (IL-6+IL-1b)-induced CRP expression in 
both proximal 157 bp and 300 bp region. Our results suggest that the STAT3 (-134) site alone 
does not contribute to enhance CRP expression but rather regulates the interaction/crosstalk 
between other transcription factors as mutation of this site enhanced CRP expression in the 
proximal 300 bp region but not in 157 bp promoter region. Consistent with this, is the 
observation that complete elimination of STAT3 binding sites (mutated -134 and -108) reduced 
CRP expression to basal levels. This raises the possibility of the involvement of an active site 
present between -300 bp and -157 bp region that is involved in the crosstalk. Also, because the 
effect is observed in both IL-6 and (IL-6+IL-1b)-induced CRP expression, IL-6 activated 
transcription factors appear to be involved in the crosstalk. Compared to the proximal 157 bp 
region of CRP promoter, the proximal 300 bp of CRP promoter elicits a greater cytokine induced 
CRP expression. Mutation of -108 site or -134 site alone did not significantly affect this 
observation. When both STAT3 sites were mutated in the proximal 300 bp region, the cytokine-
induced expression of CRP gene was reduced to basal levels, however a similar effect was not 
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observed on the cytokine-induced CRP expression in the proximal 157 bp region. This further 
supports the possibility of a crosstalk mechanism between transcription factors present in the 
proximal 300 bp promoter region and STAT3 sites (-108 and -134) along-with other 
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Figure 4.4: STAT3 binds to its cognate site at position -134 on the CRP promoter and 
regulates cytokine (IL-6 and IL-6 + IL-1β)-induced CRP expression. (A-C) Luciferase 
transactivation assay shows the effect of mutated STAT3 site at -134 on cytokine (IL-6 
and IL-6 + IL-1β)-induced CRP expression. Hep3B cells were transfected with Luc-157 
WT and Luc-157 mS (-134) (A), Luc-300 WT and Luc-300 mS (-134) (B), and Luc-157 
mS (-134) and Luc-300 mS (-134) CRP promoter constructs. (D-F) A luciferase 
transactivation assay, where the effect of mutated STAT3 sites at -108 and -134 on 
cytokine (IL-6 and IL-6 + IL-1β)-induced CRP expression, is shown. Hep3B cells were 
transfected with Luc-157 WT and Luc-157 mS (-108) + (-134) (D), Luc-300 WT and 
Luc-300 mS (-108) + (-134) (E), and Luc-157 mS (-108) + (-134) and Luc-300 mS (-108) 
+ (-134) (F) CRP promoter constructs at 24 h post cytokine treatment and 40 h post 
transfection, CRP transcription was measured as Luc activity. Fold change over basal 
luciferase activity is plotted on the x-axis. Results are expressed as mean ± SD for three 
experiments. p value of < 0.05 are considered statistically significant (*). 
 
STAT3 binds to its cognate site at -165 but does not participate in the transcriptional activation 
of CRP gene expression 
       In order to investigate the role of STAT3 (-165) in cytokine [IL-6 and (IL-6 + IL1-b)] 
induced CRP expression, we performed Luciferase transactivation assays using Luc 300-WT, 
and Luc 300-mS (-165) promoter constructs, as well a, CRP promoter constructs with both -108 
and -165 STAT3 sites mutated, Luc-300 mS (-108) + (-165). IL-1b-induced CRP expression was 
similar to basal expression (data not shown). Mutation of STAT3 at -165 in the 300 bp promoter 
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region, Luc-300 mS (-165) did not affect the cytokine induced CRP expression (Fig 4.5 A). 
However, mutation of STAT3 at both -108 and -165,  significantly reduced (IL-6 + IL-1b)- 
induced CRP expression by ~75% (* ) (Fig 4.5 B), but when compared with mutation of STAT3 
at -108 and -134, the cytokine induced CRP expression is significantly greater (Fig 4.5 C).  
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Figure 4.5: STAT3 site at -165 neither activates nor regulates cytokine (IL-6 and IL-
6 + IL-1β)-induced CRP expression. Luciferase transactivation assays of Hep3B cells 
transfected with Luc-300 WT and Luc-300 mS (-165) (A), Luc-300 WT and Luc-300 mS 
(-108) + (-165) (B), and Luc-300 mS (-108) + (-134) and Luc-300 mS (-108) + (-165) 
CRP promoter constructs at 24 h post cytokine treatment and 40 h post transfection, CRP 
transcription was measured as Luc activity. Fold change over basal luciferase activity is 
plotted on the x-axis. Results are expressed as Mean ± SD for three experiments. p value 
of < 0.05 are considered statistically significant (*). 
 
These results indicate that the putative STAT3 site at -165 does not play a significant role 
in either activating or regulating CRP gene expression as the cytokine induced CRP expression 
after mutating STAT3 site at -165 was not different than WT. Furthermore, since mutation of 
STAT3 at -108  alone reduces cytokine induced CRP expression, the effect of abolition of both 












The aim of the study was to locate additional transcriptionally active, IL-6-inducible 
STAT3 binding sites in the -300/+3 region of the CRP promoter. Our major findings were 1) 
Multiple putative IL-6 inducible STAT3 binding sites, centered at position -72, -134, and -165, -
134, are located in the proximal -300 bp region of CRP promoter,. 2) IL-6 activated STAT3 
binds to its cognate site at position -134 and -165, in addition to binding to another previously 
identified site at position -108. 3) STAT3 binds to its cognate site positioned at -165 but it does 
not activate or regulate CRP gene transcription. 4) Cytokine [IL-6 and (IL-6 + IL-1b)]- induced 
CRP expression increased dramatically when STAT3 site positioned at -134 was mutated, 
however, CRP expression curtailed back at basal levels when STAT3 was unable to bind to 
either of its two sites (-134 and -108) on the CRP promoter. This effect of STAT3 was observed 
only in the proximal 300 bp region and not in the 157 bp region. Taken together, these data 
suggest that in addition to transcriptionally active STAT3 site at position -108, STAT3 binds to 
another site centered at -134 but unlike STAT3 (-108), STAT3 (-134) does not activate 
transcription but rather regulates the crosstalk of STAT3 (-108) with C/EBPb (-222) and 
C/EBPb-b-NFkB complex (-52/-47) in the -300/+3 region of CRP promoter.  
In humans, the acute phase nature of CRP has been observed in various acute and chronic 
inflammatory states (1-6). Because CRP is a hepatocyte derived protein, the regulation of its 
synthesis at the transcriptional level has been studied and observed in various hepatocyte derived 
cell lines such as Hep3B. The activation of CRP gene expression occurs in response to IL-6 and 
IL-1b wherein IL-6 induces CRP expression via activation and binding of transcription factor 
C/EBPβ to its sites centered at position -52 and -222 and STAT3 to its site centered at position -
 119 
108 respectively, on the CRP promoter (12,13,17, 26, 29). IL-1b alone, in contrast, does not 
induce CRP expression but rather synergistically enhances IL-6 induced expression via 
activation and binding of NF-kB to its site centered at position -69 and a nonconsensus kB site 
centered at position -47 on the CRP promoter (8,9,25). Initially, the proximal 157 bp region of 
CRP promoter was found to be sufficient to induce CRP expression (9,13) but later it was 
reported that the proximal 300 bp region induces more CRP expression compared to the 157 bp 
region alone. One of the possible explanations for the differential induction of CRP expression 
between the -157/+1 and -300/+3 regions of the promoter can be attributed to the presence of an 
additional C/EBPb site at position -222. No additional NF-kB sites have been found between -
157 bp and -300 bp region of CRP promoter. Also, in the proximal 300 bp region of the CRP 
promoter, the presence of additional STAT3 responsive sites have not been sought yet. 
In the current study, we found multiple putative IL-6 inducible STAT3 binding sites, 
located at position -72, -134, and -165 respectively, in addition to the previously reported 
transcriptionally active STAT3 site at position -108. Out of these newly identified putative 
binding sites, STAT3 was found to bind to its cognate site at position -134 and -165. Although, 
STAT3 binds specifically to TT(N)4AA or TT(N)5AA motifs, the spacing between the TT and 
AA core half-sites affects the ability of STAT3 to bind to its responsive elements on the CRP 
promoter. Other STAT complexes have the ability to bind to TT(N)5AA motifs while STAT3 
binds specifically to TT(N)4AA motifs (30). This explains the inability of putative STAT3 site 
positioned at -165 to activate transcription since it contained TT(N)5AA motif. The other 
putative STAT3 site at -72 remains to be evaluated and studied further since this area of CRP 
promoter contains overlapping binding sites for various constitutively active transcription factors 
such as HNF-1, HNF-3 and a repressive transcription factor Oct-1 along with a NF-kB binding 
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site (8,12,19,32).  
 Fig 4.6 depicts our hypothetical model based on the findings in the current study 
illustrating the role of STAT3 site at position -134 in regulating CRP gene expression. The 
proposed mechanism of regulation of CRP gene transcription in lieu of STAT3 (-134) is as 
follows: 1. As shown in Fig 4.5 A, when IL-6 activated STAT3 binds to its cognate site at 
position -134 and -108, CRP transcription is activated by STAT3 (-108) and other transcription 
factors; 2. Mutation or abolition of STAT3 (-134) leads to enhanced IL-6 and (IL-6 + IL-1b)-
induced CRP expression in contrast to STAT3 (-108) wherein its abolition leads to decreased 
CRP expression. The effect of mutation or abolition of STAT3 (-108) on CRP expression is 
observed only in (IL-6 + IL-1b)- induced transcriptional activation and not in IL-6 induced 
transcriptional activation alone; 3. Also, abolition of both STAT3 binding sites, i.e., STAT3 (-
108) and STAT3 (-134) completely diminishes CRP expression down to basal levels. Therefore, 
STAT3 (-134) acts as a regulatory site for STAT3 (-108) wherein it regulates the crosstalk of 
STAT3 (-108) with other transcription factors. Since, similar effect of STAT3 (-134) is not 
observed in proximal 157 bp region, we hypothesize that C/EBPb site at position -222 is 
involved in the crosstalk with STAT3 (-108). Along with it, the discrepancy in the IL-6 and (IL-6 
+IL-1b)-induced activation of CRP transcription by STAT3 (-108) further raises the possibility 
of the involvement of NFkB in the crosstalk mechanism since NFkB is the only transcription 
factor induced by IL-1b; and 4. Taken together, as shown in Fig 4.6 B, the absence of STAT3 (-
134) enables STAT3 (-108) to cross talk and form a complex with C/EBPb (-222) and this 
STAT3- C/EBPb complex further cross-talks with C/EBPb-NFkB complex (-52/-47).  
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Figure 4.6: A hypothetical model representing the role of STAT3 site at position -134 in 
regulating CRP expression. (A) Cytokines [IL-6 and (IL-6 + IL-1b)] induce CRP 
expression of WT promoter (-300/+3) via activation of various transcription factors such 
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69/-52; green). Mutation of STAT3 (-134) increases cytokine induced CRP expression 
while mutation of STAT3 (-108) decreases (IL-6 + IL-1b)-induced CRP expression. (B) 
Deletion of STAT3 (-134) allows STAT3 (-108) to crosstalk with C/EBPb (-222) and this 
C/EBPb-STAT3 complex further cross-talks with C/EBPb- NFkB complex (-69/-52). 
These cross-talks, highlighted in red, mediates cytokine induced CRP expression. 
 
The mechanism of synergy or crosstalk between C/EBPb, STAT3, and NF‐κB has been 
observed in transactivation of CRP gene expression (33). In addition to CRP gene promoter, 
synergy between these transcription factors has also been observed to induce expression in 
promoters of various other model proteins such as synergistic interaction between NF‐κB and 
C/EBPβ (26,27,29,35-37), NF‐κB and STAT proteins (37-40), and C/EBPβ and STAT proteins 
(41-44). Our observation that STAT3- C/EBPb complex (-222/-108) crosstalk with C/EBPb-
NFkB complex (-52/-47) is based on the previously reported studies that shows that NF-κB p65 
inhibits STAT3 dependent activation of gene. Therefore, STAT3 cannot crosstalk with NF-κB 
site at position -69 since it contains p50-p65 heterodimers. In contrast, NF-κB p50 acts in 
synergy with STAT3 to activate gene transcription (20) and NF-κB p50 has been reported to 
form a complex with C/EBPb on the CRP promoter via the nonconsensus κB site (-47) 
overlapping the proximal C/EBP binding site (-52) (26). Another critical regulatory region on the 
CRP promoter that participates in transactivation of CRP gene is the -54 to -74 region, where 
NF-κB, HNF-1, HNF-3, and Oct-1form complexes. STAT3 has been reported to form a 
transcriptional complex with c-Fos and HNF-1a that aid in the synergistic induction of CRP 
gene expression (45). This raises the possibility that STAT3 might be involved in regulating 
CRP gene expression via the -54 to -74 region. However, this is just a speculation and needs to 
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be studied in detail further. 
In summary, we report another STAT3 binding site at position -134 in addition to the 
transcriptionally active STAT3 site at position -108 and in contrast to STAT3 (-108) that 
activates transcription of the CRP gene, STAT3 (-134) regulates CRP transcription by regulating 
the STAT3 (-108). This study also provides a proof of principle for a possible mechanism of 
crosstalk between STAT3 (-108), C/EBPb (-222) and C/EBPb-NF-κB p50 (-52/-47). Further 
studies using overexpressed STAT3 would provide more insight into the mechanism of 
activation and transcriptional regulation of CRP gene by STAT3. Also, future studies at 
chromatin levels need to be addressed as transiently transfected promoter constructs are not 
appropriate models for endogenous genes due to the packaging of these genes in chromatin 
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Abbreviations 
CRP                         C-reactive protein 
C/EBP                     CCAAT/enhancer-binding protein 
IL-6                         Interleukin-6 
IL-1b                       Interleukin-1b 
Luc                          Luciferase 
NF-kB                     Nuclear factor kappaB  
Oligo                       Oligonucleotide 
WT                          Wild-type 
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            The major findings of our studies were: 
 
1. A non-native pentameric CRP, F66A/T76Y/E81A mutant CRP, created by site-directed 
mutagenesis, binds to atherogenic LDL at physiological pH, i.e, it does not need the 
presence of an acidic environment to do so unlike native pentameric CRP.  
2. F66A/T76Y/E81A mutant CRP demonstrated protection against atherosclerosis by 
decreasing the extent of atherosclerotic lesions along the aorta and slowing the 
progression of the disease. This atheroprotective effect of mutant CRP was observed in a 
site-specific manner as it showed an effect on lesion area in the whole aorta of HFD-fed 
LDLR-/- mice but had no effect on the size of atherosclerotic lesions in the aortic root. 
3. Administration of F66A/T76Y/E81A mutant CRP did not affect the lipoprotein, i.e., 
HDL and LDL profile of HFD-fed LDLR-/- mice. Therefore, non-native pentameric 
human CRP that is a structurally altered form of native pentameric human CRP, is an 
atheroprotective molecule. 
4. CRP from an evolutionary distant species Limulus Polyphemus, Limulus CRP, is different 
than native pentameric human CRP. Limulus CRP is a 300 kDa protein that exists as a 
dodecamer with two rings of six subunits each with differential glycosylation patterns, as 
opposed to human CRP which is a 120 kDa pentameric, non-glycosylated protein. 
5. Limulus CRP exists in different isoforms that possess differential affinities for PCh and 
PEt containing ligands. Limulus CRP, purified either by PCh or by PEt, can recognize 
and bind to immobilized, denatured, and aggregated proteins in a calcium independent 
manner, at physiological pH.  
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6. The ligand recognition function of Limulus CRP is different than native pentameric 
human CRP but overlaps that of the non-native pentameric human CRP. 
7. Therefore, ancient CRP such as Limulus CRP, inherently had the ability to bind to 
pathogenic proteins in a physiological environment. However, over the course of 
evolution, the structure of CRP changed and in order for CRP to recognize and bind to 
such pathogenic and toxic proteins an acidic or inflammatory environment was needed.  
8. The proximal 300 bp region of human CRP promoter elicits a higher IL-6 mediated 
response when compared to the proximal 157 bp region. The proximal 300 bp region was 
found to contain three putative STAT3 binding sites, centered at position -165, -134, and 
-72, in addition to the known transcriptionally active site at position -108. 
9. Amongst the identified, putative STAT3 binding sites, IL-6 activated STAT3 was found 
to bind to its cognate site at positions -134 and -165, in addition to binding to another 
previously identified site at position -108. 
10. Cytokine [IL-6 and (IL-6 + IL-1b)]- induced CRP expression was shown to increase 
dramatically when STAT3 was unable to bind to its site positioned at -134, however, 
CRP expression curtailed back at basal levels when STAT3 was unable to bind to either 
of its two sites (-134 and -108) on the CRP promoter. This effect was observed only in 
the proximal 300 bp region and not in the 157 bp region. Taken together, these data 
suggest that in addition to transcriptionally active STAT3 site at position -108, STAT3 
binds to another site centered at -134 but unlike STAT3 (-108), STAT3 (-134) does not 
activate transcription but rather regulates the cross-talk of STAT3 (-108) with possibly, 
C/EBPb (-222) and C/EBP-b-NFkB complex (-52/-47) in the -300/+3 region of CRP 
promoter. 
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CRP has been linked to atherosclerosis, a chronic inflammatory disease, in terms of 
higher circulating levels, deposition at atherosclerotic lesion, and co-localization with LDL and 
macrophages within lesions. To elucidate the role of CRP as either a pro-atherogenic protein or 
an anti-atherosclerotic protein, various studies were performed using different animal models of 
atherosclerosis wherein native CRP was administered either passively or transgenically. In all 
studies, CRP was found to be neither pro-atherogenic nor anti-atherosclerotic with the exception 
of one study (84), where CRP was shown to slow the progression of the disease.  
Human CRP has been shown to exists in two pentameric structural conformations, native 
and non-native and the ligand recognition functions of these two structural conformations differ. 
A micro-inflammatory environment is required by CRP to change its structure from a native 
pentameric state to a non-native pentameric state, that can be achieved in vitro by exposure to 
biological modifiers such as hydrogen peroxide, hypochlorous acid or even acidic pH, but this 
structural change is reversible at physiological pH. Non-native pentameric CRP acquires the 
property to recognize and bind to immobilized, aggregated, and pathogenic proteins as opposed 
to native pentameric CRP. Previous lab studies have shown that native CRP binds to E-LDL at 
physiological pH and this CRP-E-LDL complex prevents foam cell formation (88). However, it 
does not bind to ox-LDL unless the LDL is sufficiently oxidized to expose its PCh moieties. 
Non-native CRP binds to E-LDL with higher avidity compared to native CRP and binds to ox-
LDL irrespective of the extent of oxidation.  
Atherosclerotic lesions are often characterized as inflammatory sites wherein acidic pH 
predominates along with changes in the redox environment due to free radical generation. 
Further extending our current understanding of the role of CRP in atherosclerosis is the fact that 
the disease development differs between animal models and humans. This raises the possibility 
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that the atherosclerotic lesions in animal models might lack a suitable acidic micro-environment 
necessary for native CRP to  undergo the required structural change and therefore, could not bind 
to atherogenic LDL. In this study, we used a modified CRP, F66A/T76Y/E81A (mutant CRP), 
created by site-directed mutagenesis, that binds to atherogenic LDL without the requirement of 
an acidic pH and we found that this mutant CRP delays and inhibits the progression of 
atherosclerosis in a site specific manner using LDLR-/- mouse models.  
This study provides a proof of principle for the atheroprotective ability of CRP, wherein 
non-native CRP can be used as a novel therapeutic tool for treatment against atherosclerosis. One 
of the drawbacks of this study is that it is a single dose-one regimen model. There is a possibility 
that the amount of CRP administered was inadequate and CRP was not able to display an affect 
in its full capability, as we observed a site-specific atheroprotective effect. Future studies 
employing a non-native CRP transgenic mouse model on LDLR-/- background may provide 
further validation of the atheroprotective ability of this molecule along-with a comparative study 
using another atherosclerosis mouse model such as HFD-fed ApoE-/- mice. Another drawback is 
that no mechanism of action regarding how CRP affected the development and progression of 
atherosclerosis could be defined. The proposed mechanism of action is that non-native CRP 
recognizes and binds to modified LDL and prevents foam cell formation by blocking their uptake 
by macrophages. Further studies to support the proposed mechanism of action and to define 
other potential mechanisms that are responsible for the observed protective effect of CRP in 
atherosclerosis, are required. Atherosclerosis, being a major cause of cardiovascular mortality in 
developed countries, and inflammation playing a major role in it, constantly compels the need to 
find alternative treatments as available treatments such as statins or other cholesterol lowering 
drugs presents with side-effects and the natural treatment provide with contradictory results. 
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Using a slightly altered component of the immune system itself, as a therapeutic molecule might 
prove to be beneficiary. 
CRP is an evolutionarily conserved protein that has been found in every organism where 
its presence has been sought. Over the course of evolution, the structure of CRP changed. Based 
on our finding in the study above, that a non-native pentameric human CRP acts as an 
atheroprotective molecule, it is imperative to understand the evolution of the structural change of 
CRP. Therefore, a parallel comparison of structure-function relationship of CRP between an 
evolutionary distant specie and humans would be useful. The conservation of CRP amongst 
various species across the animal phyla, led us to conclude that CRP is an important molecule of 
the immune system as it evolved along with the development of the entire immune system in 
terms of its structure and function. The sites that are relevant for the function of CRP, such as 
PCh-binding site, C1q-binding site, and an intrinsically disordered region, are also conserved 
amongst different species.  
Using Limulus polyphemus as a model invertebrate organism that is also an evolutionary 
distant species, we studied the evolution of function CRP in terms of its structure. Unlike human 
CRP, Limulus CRP is a glycosylated protein that has varying affinities for PCh and PEt ligands. 
Surprisingly, human CRP do possess sites of glycosylation but they are hidden in its native 
conformation and therefore provide no functional advantage to native CRP. Limulus CRP is 
known to exist in three isoforms due to variable glycosylation (54). The isoform of Limulus CRP 
that has higher affinity for PCh was called as CRP-I (PCh-binding Limulus CRP) and the one 
that has higher affinity for PEt was called CRP-II (PEt-binding Limulus CRP). In order to see if 
these carbohydrate moieties have any role in the structure-ligand function of Limulus CRP, we 
de-glycosylated both CRP-I and CRP-II and found that the ability of these proteins to recognize 
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and bind to immobilized, denatured and aggregated proteins significantly decreased 
(approximately 100 fold) when compared to its glycosylated counterparts. However, upon 
exposure to acidic environment, they regained their ligand-recognition function. Therefore, de-
glycosylated Limulus CRP behaves similar to native human CRP and native glycosylated 
Limulus CRP behaves similar to non-native human pentameric CRP. We conclude that though 
the ligand-binding properties of Limulus CRP are not identical to that of native human CRP, they 
overlap the ligand-binding properties of non-native pentameric human CRP that can be generated 
in inflammatory microenvironments. Also, changing the glycosylation state of Limulus CRP, 
alters its ligand-binding property to overlap with that of native human CRP.  
The drawback of our study is that we could not de-glycosylate the protein completely and 
hence, could not understand the importance of the presence of carbohydrate moieties on the 
protein, since glycosylation is the major aspect where Limulus CRP differs from human CRP. 
Additionally, the enhanced ability of Limulus CRP to recognize and bind pathogenic proteins, in 
the presence of an acidic environment could not be understood. Further studies are required to 
understand the ligand-recognition functions between human CRP and Limulus CRP, in lieu of  
the glycosylation pattern along-with the presence of an acidic environment. In our study above, 
we showed the atheroprotective ability of a non-native pentameric human CRP whose ligand 
recognition functions parallels with native Limulus CRP. These effector functions of CRP that 
lies downstream of the recognition functions are dependent on the structural changes in the 
protein. Studies on structure-function relationships of CRP from most species is unknown and 
more studies are required from all species including invertebrate and vertebrate in order to have a 
complete understanding of the evolution of this protein. 
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Over the course of evolution, in addition to the structure, it appears that the gene 
expression of CRP changed from a constitutive protein to an acute phase protein. The 
concentration of CRP increases drastically, from several hundred to thousand fold, following an 
inflammatory stimulus. The regulation of CRP gene expression occurs at transcriptional level via 
various cytokine induced and constitutively active transcription factors. Since, CRP is a 
hepatocyte derived protein, various hepatic cell lines have been used to study its gene expression. 
Hep3B is the most commonly used cell line and the major cytokines that drive CRP transcription 
in these cell lines are IL-6 and IL-1b. IL-6 alone, or in synergy with IL-1b induces CRP 
expression. The proximal 157 bp region of the CRP promoter has been shown to be sufficient to 
induce CRP transcription in response to IL-6. We recently found that the proximal 300 bp region 
of the CRP promoter elicits a greater IL-6 response compared to the 157 bp region.  
A previous study identified STAT3, an IL-6 inducible transcription factor, in activating 
CRP gene transcription via binding to its site at position -108 on the promoter (83). In this study, 
we identified multiple IL-6 inducible STAT3 binding sites on the proximal 300 bp region of 
CRP promoter. We found that, in addition to transcriptionally active STAT3 site at -108, STAT3 
binds to its cognate site at position -134. We propose that instead of activating CRP expression, 
this site regulates CRP transcription via possibly regulating the cross talk between STAT3 at -
108 and other IL-6 and IL-1b inducible transcription factors. This study provides a proof of 
principle for a possible mechanism of crosstalk between STAT3 (-108), C/EBPb (-222) and 
C/EBPb-NF-κB p50 (-52/-47).  
The drawbacks of the study are that these findings are Hep3B cell line specific and 
studied on a defined, short DNA sequence of CRP promoter. It is possible that the present study 
for understanding the induction of CRP transcription in response to cytokines might not be 
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reproducible when using transgenic mice as the defined conditions and cytokine treatments used 
might not correlate with the physiological system of the transgenic mice (85). In addition, 
transcription of CRP or any gene occurs via interaction of variable transcription factors that 
regulates the transcription of the gene either positively or negatively. In vitro transcriptional 
studies using shorter DNA sequences might produce results that could not be reproduced when 
longer sequences are used, as some regulatory elements might be located several base pairs away 
(86). Future studies using longer DNA sequences of CRP promoters and overexpressed STAT3 
would provide more insight into the mechanism of activation and transcriptional regulation of 
CRP gene by STAT3. Additionally, these findings need to be reproduced by using other 
hepatocyte derived cell lines such as HepG2, Huh7, and primary human hepatocytes. Also, 
future studies at the chromatin levels needs to be addressed as transiently transfected promoter 
constructs are not appropriate models for endogenous genes due to the packaging of these genes 
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Supplemental data  for Chapter 2 
CRP is an atheroprotective molecule 
 
Methods 
Atherosclerotic lesion measurement in the aorta (en face) 
Formalin-fixed aortae were cut open longitudinally (en face) and pinned flat on a 
standard black wax dissection pan using 0.15 mm black anodized pins. Pinned aortae were 
stained with Sudan IV for lipid rich deposits in atherosclerotic lesions. Briefly, aortae were first 
washed with 1X PBS and then with 70% ethanol for 5 minutes. Aortae were stained with Sudan 
IV solution [0.5% Sudan IV in an acetone-absolute ethanol solution (1:1)] for 15 minutes and 
then washed with 80% ethanol for 3 minutes in order to remove background stain. Aortae were 
then washed with running water followed by 1X PBS. Pinned aortae were digitally 
photographed. Thus, a total of 120 aortae (60 for untreated group and 60 for mutant-CRP treated 
group) were processed and stained. The atherosclerotic lesion area (red colored deposits) was 
determined and measured using ImageJ software.  
 
Aortic root atherosclerotic lesion measurement 
For aortic root atherosclerotic lesion measurement, OCT-embedded heart tissue along 
with aortic root was mounted in a Leica CM1850 cryostat. 8-μm cross-sections were collected 
starting at the first appearance of the aortic valve leaflets, on a Superfrosted plus microscope 
slide (Fisher, cat# 12-550-15). Cross-sections were collected until the of the aortic valve leaflets 
disappearance and alternating cryosections from each mouse were stained with oil-red O for 
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lipids and counterstained with hematoxylin. Briefly, cryosections were air dried at RT for 30-40 
minutes and then incubated in ice-cold neutral-buffered 10% formalin for 10 minutes followed 
by rinsing using tap water first and then with distilled water (DI). Cryosections were then 
incubated in 60% isopropanol (diluted with water) for 45 seconds and stained with fresh Oil Red 
O solution (ORO: Stock ORO - 0.5g ORO powder in 100 ml isopropanol; working ORO- 60 ml 
stock ORO + 40 ml DI) for 15 minutes under constant, low agitation. Following staining, 
cryosections were rinsed with 60% isopropanol for 30 seconds first and then twice with DI. 
Cryosections were counterstained with hematoxylin for 30 seconds and rinsed in running tap 
water for 3 minutes. Cryosections were then mounted with a water-soluble mounting medium 
(glycerol gelatin) at 55 oC. Images were digitally captured with an Olympus BX41 microscope 
equipped with a MicroPublisher 5.0 RTV CCD color camera (QImaging). Thus, a total of 120 
hearts (60 for untreated group and 60 for mutant-CRP treated group) were processed. 
Approximately 48-72 cross-sections were collected per heart and every alternate cross-section 
were stained for lipids. Lesions in the aortic root (red colored areas) were measured using the 
Image-J software. Measurements were performed in a blind fashion.  
 
CRP immunostaining 
Cryosections were thawed, air dried for 1 hour and, fixed in ice-cold acetone for 10 
minutes.  Sections were then washed with 1X PBS for 5 minutes, air dried and circled using a 
hydrophobic barrier (ImmEdge, Vector laboratories, cat # H-4000). Immunostaining was 
performed with Vectastain ABC Elite kit (Vector laboratories, cat # PK-6100) and 
manufacturer’s instructions were followed. CRP was detected with Rabbit anti-CRP (Millipore, 
10 µg/ml/section). Color was developed using DAB as substrate (Vector laboratories, ImmPACT 
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DAB, cat # SK-4105). Macrophages were detected with Rabbit anti-CD68 for pan macrophages 
(ThermoFisher Scientific, cat# PA5-78996; diluted 1:100) and Rabbit anti-CD163 for M2 
macrophages (abcam, cat# ab213612; diluted 1:100). Sections were counterstained with methyl 
green. Images were digitally captured with an Olympus BX41 microscope equipped with a 
MicroPublisher 5.0 RTV CCD color camera (QImaging).  
 
Measurement of circulating cytokines and CRP in the plasma of LDLR-/- mice 
Plasma was collected from whole blood via cardiac puncture at the time of sacrifice using 
EDTA as an anti-coagulant. Cytokines were measured in the pooled plasma samples, at every 
given week point, with Bio-plex mouse cytokine group I 8-plex assay kit (Lot # 64140214). 
Cytokine measured were IL-1b, IL-6, TNF-a, IL-4, IL-10, IL-12, and IFN-g. Manufacturer’s 
instructions were followed. Mutant CRP levels were measured by ELISA in the plasma samples 
of five out of twelve randomly selected mice at every given week point. Briefly, microtiter wells 
were coated with anti-CRP IgG (diluted 1:1000 in 1X TBS) and incubated overnight at 40 C. 
Wells were blocked with TBS containing 0.5% gelatin for 45 minutes followed by addition of 
pooled plasma samples, diluted in buffer containing 1X TBS, 0.1% gelatin, 0.02% Tween 20 
(ELISA buffer, pH 7.2). Wells were incubated with plasma samples for 2 h at 37 °C. After the 
CRP incubation step, the wells were washed with ELISA buffer and rabbit anti-CRP antibody 
(Sigma, diluted 1/1000 in ELISA buffer), was used (100 μl/well, 1 h at 37 °C) to detect bound 
CRP. HRP-conjugated donkey anti-rabbit IgG (GE Healthcare), diluted in ELISA buffer, was 
used (100 μl/well, 1 h at 37 °C) as the secondary antibody. Color was developed using ABTS as 





For atherosclerotic lesion measurement in the whole aorta and aortic root, median total 
lesion was reported and medians were compared. Data was analyzed using non-parametric test 
(Mann-Whitney test) using Graphpad Prism software. p < 0.05 was considered statistically 
significant. For analysis of circulating cytokines and CRP in the plasma, data is represented as 
mean + standard deviation and unpaired student t-test was used to analyze statistically significant 
















F66A/T76Y/E81A mutant CRP significantly decreased atherosclerotic lesion in the aortae 
(en face) of LDLR-/- mice 
To investigate the effect of mutant CRP on the early stages of development of 
atherosclerosis in LDLR-/- mice, en face atherosclerotic lesion area was analyzed. The 
experiment was performed twice with n=6 mice in each group at every given data collection time 
point. The data are presented as a combination of two independently performed experiments. 
Administration of mutant CRP had no effect on the en face atherosclerotic lesion at 1, 3, and 5 
weeks but, at 7th and 9th week (7 weeks: 8 weeks on high fat diet and 7 weeks of mutant CRP 
injections, 9 weeks: 10 weeks on high fat diet and 9 weeks of mutant CRP injections), the size of 
atherosclerotic lesion area in mutant CRP treated mice was significantly lower when compared 
to the lesion area in untreated mice (Fig A.1). In comparison to the untreated mice, the lesion 
area was 39% less in mutant CRP treated mice at 7th week (p = 0.007) and 42% less in mutant 
CRP treated mice at 9th week (p = 0.002). Also, in untreated group the disease progressed in an 
incremental manner from week 1 through week 7 and stayed constant until week 9 but similar 
disease progression was not observed in mutant CRP treated group where the disease progressed 
from week 1 through week 5 and stayed almost constant until week 9. This data suggest that 
mutant CRP decreased the atherosclerotic lesion area in the aortae of LDLR-/- mice between 8 
and 10 weeks of high fat diet and 7 and 9 weeks of mutant CRP administration and prevented the 








Figure A.1: F66A/T76Y/E81A mutant CRP reduces atherosclerosis in the whole aorta of 
LDLR−/−mice. Quantification of total atherosclerotic plaque or lesion coverage in en 
face aorta specimens from untreated and mutant CRP treated LDLR−/− mice maintained 
on a high fat diet is shown. The scatterplot represents the quantification of total 
atherosclerotic lesion coverage in en face aorta specimens from untreated and mutant 
CRP treated LDLR−/− mice. Data were collected at 5 different time points, i.e, 1, 3, 5, 7, 
and 9 weeks of mutant CRP administration at alternate days (TBS was injected for 
untreated group). A scatterplot of total atherosclerotic lesion coverage is shown. Each 
symbol represents the total area of the whole aorta that stained positively for Sudan IV in 
individual untreated (blue) or mutant CRP treated (green) LDLR−/− mice. Horizontal 
black lines indicate median total lesion area in the whole aorta for each group of animals. 
Asterisks (red) denote statistically significant differences between groups (*p < 0.05). 
CRP      - +         - +        - +         - +         - +  
No. of injections                4                    11                 18                 25                 32





Total lesion area 
x 10 3( µM2 )
p = 0.33 p = 0.25 p = 0.007 p = 0.002
* *
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Statistically significant differences in total lesion coverage is determined by Mann 
Whitney test. 
 
The aortic root atherosclerotic lesion area of LDLR-/- mice was unaffected by 
F66A/T76Y/E81A mutant CRP. 
Another parameter to investigate effect of mutant CRP on the early stages of 
atherosclerosis development in LDLR-/- mice was cross-sectional analysis of ORO stained aortic 
root sections. The experiment was performed twice with n=6 mice in each group at every given 
week time point. The data are presented as a combination of two independently performed 
experiments. Mutant CRP did not affect the atherosclerotic lesion area in the aortic root at any 
given time point specifically. It neither decreased the lesion area nor delayed the progression of 
the disease, as observed in the first set of experiment (Fig A.2). Hence data suggests that mutant 








CRP     - +         - +        - +         - +         - +  
No. of injections               4                  11                18                  25                32
Week of sacrifice   1         1         3        3         5         5        7        7         9        9 
Total lesion area 
( mM2 )
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Figure A.2: F66A/T76Y/E81A mutant CRP did not affect the lesion progression in the 
aortic root of LDLR−/−mice. Quantification of total lesion area in 8 µm thick aortic root 
sections covering the length of the aortic root (from the beginning of the appearance of 
aortic valves until the disappearance of valves) from untreated and mutant CRP treated 
LDLR−/− mice maintained on a high fat diet is shown. Data was collected at 5 different 
time points, i.e, 1, 3, 5, 7, and 9 weeks of mutant CRP administration at alternate days 
(TBS was injected for untreated group). A scatterplot of total atherosclerotic lesion 
coverage in the aortic root is shown. Each symbol represents the total area of the aortic 
root that stained positively for ORO in individual untreated (blue) or mutant CRP treated 
(green) LDLR−/− mice. Horizontal black lines indicate the median of total aortic root 
lesion area for each group of animals.  
 
The levels of circulatory cytokines were sparsely detectable in the plasma of LDLR-/- mice 
In order to analyze the effect of mutant CRP administration in systemic circulation, 
circulating levels of pro-inflammatory and anti-inflammatory cytokines were measured in both 
untreated and mutant CRP-treated mice (Table A.1). Unfortunately, the cytokines were either 
sparsely detectable or not detectable at all. Anti-inflammatory cytokines IL-4 and IL-10 were 
undetectable while pro-inflammatory cytokines IL-6, IL-1a, and TNF-a were sparsely 
detectable. Therefore, the effect of mutant CRP on the cytokine profiling in the plasma of LDLR-





























2.41 ± 1.92 
 
2.49 ± 0.73 
 
9.48 ± 10.9  
 
4.33 ± 6.12 
 
118.19 + 90.07      41.49 + 1.93 
 
 
26.32 + 1.93          25.2 + 0.33 
 
 
21.36 + 1.28          91.3 + 7.23  
 
 
31.34 + 1.29         33.73 + 18.83 
 
 




1.39 ± 0.73 
 
2.57 ± 0.27 
 
1.72 ± 0.69 
 




1.22 ± 0.28 
 








2.11 ± 0.24 
 








2.12 ± 1.55 
 
1.32 ± 0.33 
 
0.84 ± 0.91 
 
0.86 ± 0.18 
 
Table A.1: Levels of circulating pro-inflammatory cytokines were analyzed in pooled 
plasma samples from experiment 1 and experiment 2 respectively and results are 
expressed as mean + SE. Samples were collected at five different time points, i.e, 1, 3, 5, 
7, and 9 weeks of mutant CRP administration at alternate days (TBS was injected for 
control group). No statistically significant differences were found between the untreated 
and mutant CRP treated groups at any time point (ND: not detectable). 
 
Mutant CRP levels in the plasma of LDLR-/- mice 
To further evaluate the presence of administered mutant CRP in the plasma of LDLR-/- 
mice, CRP ELISA was performed. CRP levels observed in untreated mice are considered 
baseline levels, as these mice did not receive mutant CRP. Amongst all week points, mutant CRP 
was detected only after 1st week of mutant CRP administration (Table A.2). This could be 
explained in light of the half-life of this mutant CRP. Because mutant CRP was injected every 48 
hours and the half-life of this CRP is approximately 15-20 hours, there is a possibility that the 
mutant CRP was cleared from the system by the time plasma was collected. The detection of 
mutant CRP at certain time points above baseline levels can also be explained in part of the 
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sample collection time since, we injected mutant CRP every 48 hours and the sample collection 
time varied between 24 hours post mutant CRP administration and 48 hours post mutant CRP 









CRP concentration (ng/ml) 







19.4 ± 2.61 
 




25.8 ± 5.81 
 




54.4 ± 17.01 
 




64.6 ± 47.34 
 




87 ± 31.32 
 
79 ± 17.73 
 
Table A.2: Circulating levels of mutant CRP were analyzed in pooled plasma samples 
from experiment 1 and experiment 2 respectively and results are expressed as mean + SE. 
Samples were collected at five different time points, i.e, 1, 3, 5, 7, and 9, weeks of mutant 
CRP administration at alternate days (TBS was injected for control group. 
 
Mutant CRP did not alter the MΦ1/ MΦ2 macrophage ratio at the atherosclerotic lesion 
area of LDLR-/- mice  
To evaluate the effect of mutant CRP on the inflammatory environment, immunostaining 
for pro-inflammatory macrophage (MΦ1) and anti-inflammatory macrophage (MΦ2), in the 
aortic root atherosclerotic lesions of both untreated and mutant CRP treated mice was performed 
using CD 68 as the pan macrophage marker and CD 163 as the MΦ2 macrophage marker. As 
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expected, atherosclerotic lesions stained CD 68-positive for macrophages whereas, the lesion 
area stained CD 163-negative suggesting that there were no anti-inflammatory MΦ2 
macrophages present (Fig A.3A, A.3B). This implies that the macrophages present at the 
atherosclerotic lesions were pro-inflammatory MΦ1 macrophages and these data were consistent 
for both untreated and mutant CRP treated lesions that further suggests that mutant CRP 




Figure A.3: Macrophage and CRP immunostaining in aortic root lesions. Representative 
aortic root sections from untreated and mutant CRP treated LDLR−/− mice fed on a high 
fat diet, stained for pan macrophages using CD 68 as the pan macrophage marker, is 
shown (A). CD 68-positive areas are stained brown. For MΦ2 (anti-inflammatory 
macrophages) staining, CD 163 was used as a marker (B). Positive CRP stained lesion 





CRP - +                                              
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Mutant CRP was not present at the atherosclerotic lesion in the aortic root area 
In order to test the presence of administered mutant CRP at the atherosclerotic lesion in 
the aortic root area, CRP immunostaining was performed in the aortic root lesions of both 
untreated and mutant CRP treated mice at every given data collection week point. Anti-CRP 
gave false-positive staining in the aortic root atherosclerotic lesion of untreated and mutant CRP 
treated mice (Fig A.3C). This suggests that anti-CRP (both polyclonal anti-CRP and (Fab)-
fragmented anti-CRP) was cross reacting with immune complexes present in the atherosclerotic 
lesion such as ox-LDL-IgG immune complexes. Due to the false-positive CRP staining, the 

















In this study we investigated the effect of a non-native pentameric CRP created by site-
directed mutagenesis, F66A/T76Y/E81A mutant CRP, that does not bind to PCh since the PCh 
binding site of this mutant CRP is abolished due to mutations of critical amino acids forming the 
PCh-binding pocket, i.e, Glu81, Phe66 and Thr76, on the development of atherosclerosis 
employing LDL receptor knockout mouse model of atherosclerosis. Our major findings were as 
follows: 1) F66A/T76Y/E81A mutant CRP, in the whole aorta, had an effect on the progression 
and development of atherosclerosis wherein administration of this protein significantly reduced 
the size of en face atherosclerotic lesion in LDLR-/- mice at 8-10 weeks of high fat diet and 
halted the progression of the disease post 6 weeks of high fat diet. 3) Mutant CRP showed no 
effect on the progression and development of atherosclerosis in the aortic root. 4) The effect of 
mutant CRP administration on the levels of circulating cytokines in the plasma could not be 
evaluated. 5) Mutant CRP administration did not alter the macrophage phenotype at the 
atherosclerotic lesion area. 6) The presence of administered mutant CRP could not be evaluated 
at the atherosclerotic lesion area in the aortic root. 
In the current study, we could not analyze the presence of administered 
F66A/T76Y/E81A mutant CRP at atherosclerotic lesion in the aortic root because anti-CRP 
(both polyclonal anti-CRP and (Fab)-fragmented anti-CRP) provided false-positive staining as 
mutant CRP was detected in the aortic root atherosclerotic lesion of both untreated and mutant 
CRP treated mice. Since, the lesion area in the aortic root is extremely complex, one of the 
possible reasons can be that anti-CRP was recognizing and cross reacting with immune 
complexes present in the atherosclerotic lesion such as ox-LDL-IgG immune complexes (1-2).  
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Macrophages are heterogeneous cell populations that have been shown to be present in 
the developing lesion during pathogenesis of atherosclerosis. Macrophages have the ability to 
switch from their “classically activated” pro-inflammatory (MΦ1) phenotype to an “alternative” 
anti-inflammatory (MΦ2) phenotype and vice versa, depending on the microenvironment or 
specific signals sensed by them (3-4). In order to further understand the atheroprotective effect of 
F66A/T76Y/E81A mutant CRP in lieu of its ability to alter the macrophage phenotype from anti-
inflammatory (MΦ2) to pro-inflammatory (MΦ1), we stained the aortic root atherosclerotic 
lesion for macrophages. The lesion areas were found to be macrophage-rich as they identified as 
CD68-positive while, in contrast, the lesion area stained negative for MΦ2 phenotype in both 
untreated and mutant CRP treated mice suggesting that the atherosclerotic lesion had a greater 
concentration of macrophages specifically M1 macrophages and F66A/T76Y/E81A mutant CRP 
did not affect or alter macrophage phenotype. 
Since, atherosclerosis is considered as a chronic inflammatory condition with 
concomitant increase in pro-inflammatory cytokines such as IL-6, IL-1b, TNF-a and also, it has 
been shown that native CRP can interact with modified LDL and reduce the proinflammatory 
effects produced by modified LDL and foam cells. Therefore, in order to observe the effect of 
F66A/T76Y/E81A mutant CRP on the levels of circulating cytokines in the plasma, a Bio-plex 
multi cytokine assay was performed. Unfortunately, the cytokines could not be detected as they 
were either sparsely detectable or not detectable at all. Anti-inflammatory cytokines IL-4 and IL-
10 were undetectable while pro-inflammatory cytokines IL-6, IL-1a, and TNF-a were sparsely 
detectable and hence, the effect of mutant CRP on the cytokine profiling in the plasma of LDLR-
/- mice could not be evaluated. Along with it, there were no antibodies produced against 
administered mutant CRP.  
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